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ABSTRACT. 
Excess plasma free fatty acids (FFA) are correlated with insulin resistance and are 
a risk factor for the development of type 2 diabetes. In this study we examined the effect 
of the polyphenol resveratrol on FF A-induced insulin resistance in skeletal muscle cells 
and the mechanisms involved. Incubation of L6 myotubes with the FF A palmitate 
significantly decreased the insulin-stimulated glucqse uptake. Importantly, the effect of 
palmitate was ameliorated by resveratrol. Palmitate significantly increased serine 
phosphorylation of IRS..; 1 and reduced insulin-stimulated Akt phosphorylation, an effect 
that was abolished by resveratrol. We then investigated the effect of palmitate and 
resveratrol on the expression and phosphorylation of JNK, mTOR, p70-S6K, and AMPK 
kinases. The results demonstrated that our treatments had no effect on the expression of 
these proteins. However, palmitate increased the phosphorylation of mTOR and p70-
S6K, whereas resveratrol abolished this effect and increased the phosphorylation of 
AMPK. Furthermore, all effects of resveratrol were abolished with sirtuin inhibitors, 
sirtinol and nicotinamide. These results indicate that resveratrol ameliorated FF A-induced 
insulin resistance by regulating mTOR and p70-S6K phosphorylation in skeletal muscle 
cells, through a mechanism involving sirtuins. 
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CHAPTER 1: BACKGROUND INFORMATION 
INSULIN AND THE INSULIN SIGNALLING CASCADE 
1.1 Insulin & Diabetes 
Insulin is an essential protein hormone that regulates, metabolism, growth, and 
differentiation (1;2). It was first discovered at the University of Toronto in 1921 by 
Fredrick Banting and Charles Best (1). Insulin is produced by the ~-cells of the islets of 
Langerhans located in the pancreas. Structurally, insulin consist of two chains of amino 
acids, an a-chain and a ~-chain which are linked by two disulfide bonds (3). 
Insulin has important biological effects on its main target tissues, skeletal muscle, 
liver, and adipose. It regulates carbohydrate, protein, and lipid metabolism, and cell 
growth and survival (3;4). Insulin is a major player in the regulation of blood glucose 
homeostasis. Following a meal, blood glucose levels increase, and this increase is sensed 
by the pancreas. The pancreas releases insulin which in turn promotes glucose uptake into 
skeletal muscle and fat tissue, while inhibiting glucose secretion by the liver. The net 
effect of these actions of insulin is to bring blood glucose levels back to normal. Figure 1 
depicts these effects of insulin on its target tissue following a meal (5). 
The ability of insulin to promote glucose uptake in skeletal muscle and adipose 
.. 
cells, while preventing glucose production by the liver is a very important physiological 
process (1). Lack of insulin or the inability of insulin to carry out its normal function 
leads to major homeostatic disturbances and to a disease known as diabetes mellitus. 
Diabetes is classified into two different pathologies, type 1 and type 2. Early destruction 
of the ~-cells that produce insulin leads to insulin deficiency and the type 1 diabetes 
mellitus pathology (3). Individuals with type 1 diabetes require insulin injections to 
maintain blood glucose homeostasis. In contrast, individuals with type 2 diabetes are 
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characterized by compromised insulin action, and ~-cell function. The factors mediating 
insulin resistance may be genetic and/or environmental. Obesity and reduced physical 
activity may also be contributors (3). 
Treatment of type 2 diabetes may start with increased activity/exercise, controlled 
diet, and the use of pharmaceutical agents such as metformin, thiazolidinediones (TZDs), 
and sulfonylurease (SUs) (6). Pharmacological agents are widely prescribed and have 
different mechanisms of action to help regulate blood glucose homeostasis. Metformin 
has been reported to activate AMPK which then promotes glucose uptake into skeletal 
muscle cells and adipocytes (7). The TZDs (i.e. rosiglitazone) act by binding to the 
nuclear receptor peroxisome-proliferator-activator receptor 'Y (PPAR'Y), which increases 
insulin sensitivity and decreases glucose production by the liver (8). Sulfonylureas act by 
stimulating the ~-cells of the pancreas to secret more insulin. This occurs when the drug 
binds to the ATP-dependent K+ channel of the ~-cell, causing depolarization on the ~-cell 
membrane, thereby releasing insulin into the blood stream (6). 
1.2 Glucose Transport Proteins 
Due to size and its hydrophobic properties, glucose can not freely pass through 
the cell membrane lipid bilayer. Therefore glucose, with a molecular weight of 180 is 
transferred through the plasma membrane by facilitated diffusion. A family of glucose 
transport proteins known as the GLUT family allow facilitated entry of glucose into the 
cell (1). The GLUT family consists of at least 12 different members, which are 
structurally similar to each other. All GLUT proteins have a transmembrane region that 
makes up the majority of the protein. They also contain a less conserved, asymmetric, 
exoplasmic region. Within the transmembrane regions are 12 membrane-spanning-helices, 
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which contain an N-terminal segment and a C-terminal segment in the cytoplasm and an 
extracellular N-linked oligosaccharide structure (9; 1 0). 
Meal 
\ 
t in blood glucose ! 
Fat cell ~~ Skeletal muscle 
. t 0 1 0 





Figure 1: The effect of insulin on its target tissues to regulate blood glucose homeostasis. 
The naming of each GLUT isoform follows its chronological cloning. The GLUT 
proteins were isolated and identified by cDNA cloning experiments using reverse 
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transcription polymerase chain reaction (RT-peR) (9).GLUTI was the first GLUT to be 
cloned from brain tissue. It is ubiquitously expressed in the body. GLUT2 is expressed in 
the liver, intestine, and kidneys. GLUT3 is present in the placenta, testis, and neurons 
(11). GLUT4 is the major insulin-responsive glucose transporter and is expressed in 
skeletal muscle, heart and fat tissue (9). The GLUTl, GLUT2, GLUT3 and GLUT4 
proteins have been extensively studied, while the remaining GLUT6-12 proteins are 
proteins that have no known function (9). 
Table 1 lists all of the glucose transporters identified so far, along with each 
transporter tissue expression and known function (9). Apart from differences in tissue 
distribution, the GLUT family members have different affinities for glucose. For example, 
GLUTl has a Km of20mM for glucose, GLUT2 has a Km of 42mM, GLUT3's Km for 
glucose is lOmM, GLUT4 has a Km of 2-10mM, and GLUTS does not have significant 
affinity for glucose, but rather a high affinity for fructose. The differences in glucose 
affinity by each of the GLUT family members are physiologically important in each of 
the tissues they are expressed, and playa role in the maintenance of whole body glucose 
homeostasis (9; 12). 
In the absence of insulin stimulation in muscle and fat cells, GLUT4 is localized 
in intracellular membrane vesicles, also known as GLUT4 storage vesicles (GSV's) (1). 
When insulin binds and activates its receptor, it causes receptor autophosphorylation on 
tyrosine residues and increased tyrosine kinase activity, which in tum will phosphorylate 
insulin receptor substrates (IRS). Once phosphorylated, IRS will allow 
phosphatidylinositol 3-kinase (PI3-K) to bind to it, triggering PI3-K activation. PI3-K in 
the active state will cause activation of phosphoinositide dependent kinase 1 (PDKl), 
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which will subsequently phosphorylate Akt. This sequence of events will cause the 
GSV's to translocate from there cytoplasmic location to the cell surface (as seen in figure 
2) (1;10). Once insulin is removed GLUT4 proteins cycle back to their storage sites (13). 
Table 1: GLUT protein family expression in specific target tissues (9) 
Tissue-specific expression of the GLUT proteins ! 
...................................................................................................................................................................................................... ~ ................................................................................... . 
Protein I Exp ress ion ~ Function 
................................................. : ....................... ~ .............................................. , ............. , ......... ·· ...... •· .. ,,········ .. ·• .. • .. •·•·•· ...... · ...... • .. ·000·· .......... ·· ...... • ............................................................. .. 
GLUT 1 I All tis sue I Basal uptake 
................................................. ~ ........................................................................................................................................................................................................................................  
GLUT2 . ~ Liver, pancreas ! Glucose sensing 
·················································000···· ................................................................................................................................................ : .................................................................................. .. 
GLUT3 !Brain IComplements GLUT1 
·GI"O"f'4····················TKifu·s·"ic·e·· .... ·faf,····he·a·ri··· ...... ······ .. ·········· .. · ..······ .. · ..······································Ti"n·s·uffn···re·s·po·rl"sh;·e······· ........ .. 
...................................................................................................................................................................... ·························· .. ·· .. t········ .. n ....................................................................... .
GLUT5 ! Intestine, testis, kidney, erythrocytes ! Fructose transport 
................................................. <0> .................................................................................................................. , ................................. : ................................................................................... .. 
GLUT6 I Spleen, leukocytes, brain ~ Fructose transport 
·GLlffY··········· .. ····T[jv·er························ .......................................................... ··············································"!""F·ru·c;t"o·se··ira·n·sp·o·rt· .. ····· .. ······ 
................................................. : .................................................................................................................................................... -0-................................................................................... . 
GLUT8 IT estis, brain i Fructose transport 
................................................. -0-....................................................................................................................................................................................................................................... .. 
GLUT9 ~ Liver, kidney ! Fructose transport 
................................................. -0- ....................................................................................................................................................................................................................................... .. 
GLUT 1 0 ! Liver, pancreas ! Fructose transport 
................................................. : ........................................................................................... •······· ........ ·········· .. • .. ··• .. •······• .... • .. ······000 ...... • .. • ........................................................................ .. 
GLUT 11 I Heart, muscle ~ Fructose transport 
................................................. : ................................................................................................. ••••••• .... • ...... •••• .... •• .... • .. ••••••• .. • .. •• .. 000 .. • .. •••••• ...... • ................................................................ .. 
GLUT12 IHeart, prostate !Fructose transport 
Attenuation of skeletal muscle insulin resistance by resveratrol 6 
Figure 2: Insulin signalling pathway leading to translocation of GLUT4 to the plasma 
membrane in skeletal muscle 
The importance of GLUT4 for skeletal muscle glucose transport is evident by 
studies using mice with specific GLUT4 knockout strategies. Muscle specific GLUT4 
knockout mice (muscle-G4KO) exhibit a 95% reduction in GLUT4 expression, a 40-50% 
decrease in basal glucose transport in soleus skeletal muscle, and are insulin resistant 
since they demonstrate complete abolishment of insulin-stimulated glucose uptake in 
skeletal muscle (14). Furthermore, it has also been demonstrated that the pathological 
consequences of GLUT4 homozygous allele knockouts are growth retardation, enlarged 
hearts (3-3.5 times greater that control mice), and absence of white adipose tissue (15). 
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1.3a The Insulin Receptor and the Insulin Signalling Cascade 
Insulin binding to its receptor employs many different intracellular 
molecules/proteins that relay the insulin signal downstream within the cell, leading to an 
insulin-induced cellular response. The insulin receptor belongs to a large family of cell 
surface receptors possessing intrinsic tyrosine kinase activity (16). 
Structurally, the insulin receptor is composed of two extracellular a-subunits, and 
two transmembrane /3-subunits linked by disulfide bonds, as seen in figure 3. The 0.-
subunit is composed of 723 amino acids and contains the insulin binding domain. The /3-
subunit is made up of 620 amino acids and is composed of three compartmentalized 
regions: the extracellular, transmembrane, and cytosolic domains (17). The cytosolic 
tyrosine kinase domain of the /3-subunit has an A TP binding consensus sequence and 
three clusters of tyrosine residues that can be phosphorylated in response to insulin (17). 
These three clusters are found in the juxtamembrane domain that is proximal to the cell 
surface, a regulatory region located in the center of the /3-subunit, and the COOH-tail 
region (16). 
Insulin binds to the extracellular a-subunit of the insulin receptor, which leads to 
conformational change. This results in multi site autophosphorylation of the tyrosine 
residues on the /3-subunit of the receptor, leading to increased tyrosine kinase activity 
(16). There are a total of 13 tyrosine residues in the /3-subunit of the insulin receptor (17). 
The individual sites of autophosphorylation have been recognized and correlated with the 
tyrosine kinase activity and biological action of the receptor. The key tyrosine (Y) 
residues that are phosphorylated on the /3-subunit are Y953, Y960, and Y972 of the 
juxtamembrane region, Y1146, Y1151, and Y1152 of the catalytic domain, and Y1316, 
Attenuation of skeletal muscle insulin resistance by resveratrol 8 
and Y1322 of the COOH-terminal domain. The juxtamembrane regIOn account for 
approximately 15% of total autophosphorylation activity of the receptor, while the 
catalytic domain accounts for 50%, and the COOH-terminal accounts for 30-35% (17). 
a Subunit 
'<If- Cell membrane 
f3 Subunit 
Figure 3: Schematic representation of the insulin receptor. 
Point mutations that substitute phenylalanine for a specific tyrosine residue in the 
B-cytosolic domain of the insulin receptor has shown decreased tyrosine kinase activity 
(17). The most important tyrosine residues appear to be Y1146, Yl151, and Yl152 in the 
catalytic domain of the insulin receptor. When these tyrosine residues were substituted 
with phenylalanine there was significant inhibition of insulin action (17). Furthermore, 
when all the tyrosine residues in the three domains of the B-subunit of the insulin receptor 
were substituted for phenylalanine, the biological effects of insulin were completely 
abolished. 
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1.3b Insulin Receptor Substrates 
Insulin receptor tyrosine kinase (R TK) activation leads to phosphorylation of 
insulin receptor substrates (IRS). The IRS are a family of cytoplasmic proteins that 
contain 22 prospective tyrosine phosphorylation sites that act as recognition sites for 
cellular substrates containing specific SH2 domains (16). All of the IRS proteins share a 
common NH2-terminal pleckstrin homology (PH) domain, with subsequent 
phosphotyrosine binding (PTB) domain, and a domain of varying length containing 
numerous potential tyrosine phosphorylation sites (16; IS). 
Presentl y, there are nine members of the IRS family, four IRS proteins (IRS 1-4), 
three Src-homology collagen (SHe) proteins, Grb2 associated binder-I (Gab-I), and 
p62dok (19). The IRS-l (1S0kDa) and IRS-2 (lS5kDa) have been extensively studied, and 
their role in insulin-stimulated glucose uptake and glucose metabolism has been 
established. Once IRS-l is phosphorylated, it acts as a docking protein for other SH2 
domain-containing proteins. For example, the pS5 regulatory subunit of 
phosphatidylinositol 3-kinase (PI3-K) binds to IRS-I, and this leads to the activation of 
its catalytic subunit propagating the insulin signal downstream. The IRS-3 protein is 
expressed mainly in adipose tissue, and does not playa role in glucose uptake. Similarly, 
IRS-4 is not involved in glucose homeostasis, but is highly expressed in the 
neuroendocrine tissue (19). The functions ofIRS-3 and IRS-4 are still being elucidated. 
To evaluate the involvement of IRS-I in glucose uptake and metabolism, global 
gene IRS-l knockout mice were examined (20). Mice with IRS-l knockouts 
demonstrated abnormal glucose tolerance and low birth weight, up to 40-60% less than 
their wild-type mice counterpart (20). However, these mice did not develop diabetes due 
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to the development of ~-cell hyperplasia (20). A similar study by Araujo et aI, 2005 
showed similar results in Wi star rats that experienced short-term IRS-l inhibition via an 
antisense oligonucleotide (IRS-lAS) (21). This study showed a 40% decrease in Akt 
phosphorylation and a 30% decrease in ERK tyrosine phosphorylation in the skeletal 
muscle of IRS-lAS rats. In addition, the expression of IRS-l in skeletal muscle was 
reduced by 75% (21). 
By contrast, IRS-2 is specific to insulin action in the liver, as well as ~-cell 
growth and survival. IRS-2 knockout mice exhibit only a small reduction in weight (10%), 
but develop diabetes early in life due to poor insulin secretion (20). Conversely, the role 
ofIRS-3 and IRS-4 in glucose homeostasis is negligible when compared to the IRS-l and 
IRS-2 isoforms. In fact, IRS-3 and IRS-4 knockout mice appear similar to their wild-type 
counterparts with normal insulin sensitivity (20). This evidence demonstrates that the 
IRS-l and IRS-2 proteins play a vital role in the regulation of the insulin signalling 
cascade. 
1.3c The PI3-K Pathway 
The phosphatidylinositol 3-kinase (PI3-K) protein was initially recognized as a 
signalling molecule responsible for the phosphorylation on the D-3 position of the 
inositol head group of phosphoinositides (19). This family of proteins consists of 14 
members separated into four classes of which class I, II and III are lipid kinases, and class 
IV are related protein kinases (22). In mammals both class I and class II PI3-K proteins 
have been discovered. However, only the heterodimeric p85/pliO PI3-K of the class I 
family of proteins is stimulated by insulin (19). 
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The class I family of PI3-K proteins consists of a p85 regulatory subunit that 
contains SH2 domains, and a p 110 catalytic subunit responsible for its activity. This class 
is also further subdivided into class lA and class lB. Sub-class lA incorporates the 
p 11 Oa and p 11 O~ catalytic subunit, while sub-class 1 B contains the p 11 Oy catalytic 
subunit (22). There are many isoforms of the regulatory p85 subunit as well. Each p85 
subunit contains two SH2 domains, which bind to tyrosine phosphorylated motifs on IRS 
proteins and growth factor receptors (19). The isoforms 85a, p55a, p50a, p85~, and p55y 
may all be bound by class lA catalytic subunits. Alternatively, the plIO catalytic subunit 
may be bound by the class IB catalytic subunit (19). Also, the proteins PI4-K and PI5-K 
have been shown to share a similar homology to PI3-K, but have no function in glucose 
metabolism. 
Once phosphorylated, the IRS proteins act as docking sites for the regulatory 
subunit (p85) of PI3-K that will be recruited and bind to IRS via its SH2 domain. The 
interaction of the IRS protein and the p85 subunit of PI3-K will in tum activate the 
catalytic subunit (plIO) of PI3-K. These steps lead to PI3-K recruitment to the plasma 
membrane, wherein the lipid kinase will generate a pool of lipid messenger, known as 
phosphatidylinositol (3,4,5) triphosphate (PIP3). This event will initiate a series of steps 
that include the recruitment/activation of effector proteins that carry PIP3 binding 
domains, such as phosphoinositide dependent kinase-l (PDKl). PDKI has a pleckstrin-
homology (PH) domain that recognizes various phosphoinositides generated by PI3-K 
activation (23). PH domains bind with different affinities to the phosphoinositides, which 
in tum interact with the PH domain of the serine/threonine kinase Akt, causing it to 
become activated (23). 
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Two of the widely used PI3-K inhibitors are wortmannin and L Y294002. 
Wortmannin is a naturally occurring metabolite of Penicillium funiculosum, while 
LY294002 was derived from the flavonoid quercetin (22). PI3-K inhibition by 
wortmannin is obtained in vitro at a concentration of lOnM in skeletal muscle, and works 
at higher concentration to exert its effect on PI3-K related proteins such as mTOR and 
DNA-PK. Similarly, inhibition of PI3-K with L Y294002 is observed around 50llM in 
vitro (24). Initial studies using the PI3-K inhibitors show that PI3-K plays a vital role in 
the insulin stimulated glucose uptake. Furthermore, mice lacking PI3-K expression in 
skeletal muscle suffered from impaired glucose metabolism (22). This study 
demonstrated that PI3-K is a key player in mediating the effect of insulin to promote 
glucose uptake into skeletal muscle tissue. 
1.3d The AktlPKB Pathway 
Akt/PKB (protein kinase B) is a 56 kDa insulin-activated protooncogen that 
encodes a serine-threonine kinase that is the downstream target of PI3-K (25). Akt was 
originally identified as a protein kinase with similar homology to the protein kinases A 
and C, and was thus termed PKB. In addition, Akt is the cellular homologue of the viral 
oncoprotein v-Akt, and is also referred to as c-Akt (26). There are three different 
isoforms of Akt, which are known as Aktl, Akt2, and Akt3. Aktl is the most 
ubiquitously expressed isoform in mammalian tissues. Akt2 is also highly expressed in 
the majority of tissues and organs, at levels usually lower that Aktl. Akt2 is 
predominantly found in insulin target tissues, such as adipose, liver, and skeletal muscle 
cells. On the other hand, Akt3 is expressed in low levels in mammalian cells, except for 
in the testes and brain (25). 
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All three isoforms are similar in size and structure and contain an amino-terminal 
pleckstrin homology (PH) domain, a C-terminal hydrophobic motif (HM), and a kinase 
domain (25). The PH domain facilitates the binding of Akt to the 3-phosphoinositides and 
PIP3 that are created by PI3-K (27). There are two specific sites, one in the kinase domain 
(Thr308) and the other in the C-terminal regulatory region (Ser473) that need to be 
phosphorylated for full activation of Akt (27). This kinase is cytosolic in unstimulated 
cells, and some of it translocates to the plasma membrane upon PI3-K activation, where it 
in tum becomes activated by PI3-K. In the active state, Akt will detach from the plasma 
membrane and migrate through the cytosol and into the nucleus (26). How this 
mechanism of action of Akt migration into the nucleus is achieved is currently unclear. 
Akt can become stimulated by insulin and other growth factors, such as platelet 
derived growth factor (PDGF), and epidermal growth factor (EGF) (28). Specifically, in 
skeletal muscle and adipocytes, Akt is stimulated by insulin which leads to GLUT4 
translocation and increased glucose uptake in mammalian cells. Apart from glucose 
uptake, Akt also has many mitogenic functions within the cell (26). It may help regulate 
cell size and cell survival, as well as control cellular metabolism as seen in figure 4 (28). 
To address Akt's role in glucose uptake, studies have used a constitutively active 
mutant of Akt in 3T3-LI adipocytes (28). Overexpression of a constitutively active 
mutant of Akt (Akt-myr) resulted in a significant increase in GLUT4 translocation to the 
cell membrane and increased glucose uptake, even in the absence of insulin. In addition, 
other studies have demonstrated that Akt is co-localized with GLUT4-containing vesicles 
in 3T3-LI adipocyte cells (29). Also, use of a dominant inhibitory mutant of Akt that is 
kinase-deficient, resulting from the substitution of an alanine for lysine at the 179 residue 
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in the canonical ATP-binding domain, failed to cause GLUT4 translocation to the plasma 
membrane of adipocytes, even in the presence of insulin-stimulation (28). A similar study 
by Wang et aI, 1999 investigated the role of Akt in GLUT4 translocation and glucose 
uptake in L6-GLUT4myc skeletal muscle cells (30). A constitutively active Akt protein 
created by fusion of a viral Gag protein at its N terminus (GagAkt), increased the cell 
surface density of GLUT4myc compared to control cells (30). Furthermore, the study 
also employed the use of a kinase-inactive phosphorylation-deficient Akt construct 
(substitution of alanine for the lysine at position 179 of Akt) to examine the function of 
Akt in GLUT4 translocation and insulin-stimulated glucose uptake. There was a marked 
inhibition of GLUT4 translocation to the plasma membrane and abolished insulin-
stimulated glucose uptake in L6 myotubes that had the dominant-negative Akt mutant 
(30). Taken together, these studies demonstrate that glucose uptake via GLUT4 
translocation in adipose and skeletal muscle tissue is dependent on Akt function. Figure 4 
shows some of the downstream Akt effects in mammalian cells. 
In vivo approaches using knockout mice (Aktl-I-, and Akt2-1-2) have been taken 
to examine Akt function. Aktl-I- knockout mice showed defects in both fetal and 
postnatal growth that carryon into adulthood (31). However, these mice have normal 
glucose tolerance and .insulin sensitivity. In contrast, Akt2-1- mice exhibited insulin 
resistance and became diabetic (32). These studies demonstrated the different physiologic 
roles the Akt isoforms. In addition to in vivo reports, some studies have used small 
interfering RNA (siRNA) to deplete both Aktl and Akt2 is 3T3-LI cultured adipocytes 
(33). Loss of Aktl alone caused slight impairment of insulin-stimulated glucose transport 
and had no effect on glycogen synthase kinase (GSK)-3 phosphorylation. Conversely, a 
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70% reduction of Akt2 levels alone inhibited almost half of the insulin-stimulated 
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Figure 4: The functions of Akt in the insulin signalling cascade in mammalian cells. 
INSULIN RESISTANCE IN SKELETAL MUSCLE 
1.4a Insulin Resistance in Skeletal Muscle Cells 
Skeletal muscle is quantitatively the most important target tissue of insulin, and 
defects in the mechanisms regulating insulin-stimulated glucose transport in skeletal 
muscle will lead to insulin resistance (34;35). Decreased insulin-stimulated glucose 
uptake may be due to decreased expression of the insulin receptor, reduced tyrosine 
phosphorylation of the insulin receptor or IRS-l due to decreased tyrosine kinase activity 
of the receptor. Phosphorylation and activation of downstream proteins including Akt as 
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well as GLUT4 translocation to the plasma membrane may also be diminished (36). It 
has been established that serine phosphorylation of IRS-1 leads to impairment in the 
insulin signalling cascade and a significant reduction in insulin-stimulated glucose uptake 
(34;37;38). 
Insulin resistance is highly correlated with obesity and is a risk factor for the 
development of type 2 diabetes, metabolic syndrome, and cardiovascular disease (36). It 
has been shown that insulin-induced glucose uptake in skeletal muscle is significantly 
reduced in obese individuals and patients with type 2 diabetes (36). Moreover, decreased 
expression of IRS-1 and low levels of tyrosine phosphorylation have been found in 30% 
of subjects at high risk for type 2 diabetes, such as obese individuals and subjects that are 
first-degree relatives of type 2 diabetics (39). Several signalling molecules, including 
GSK3 (40), c-Jun N-terminal kinase (JNK) (41;42), PKC's (43), NFKP (44), mTOR 
(45;46), and p70 S6K (47;48) have been implicated to mediate insulin resistance. All of 
the above molecules have been shown to induce insulin resistance by serine 
phosphorylation of the IRS-1 protein, leading to decreased insulin-stimulated glucose 
uptake in skeletal muscle and adipose cells, as seen in figure 5 (36). There are many other 
studies indicating that increased saturated free fatty acids (FF A) levels leads to insulin 
resistance in skeletal muscle by mechanisms involving the above mentioned signalling 
molecules (41;43-45;47;49;50). In the following sections a review is presented of the role 
of these signalling molecules in mediating insulin resistance. 
l.4b Insulin Resistance and Serine (ser) Phosphorylation of IRS-I 
The notion of serine phosphorylation of IRS-1 impairing insulin action was first 
demonstrated 14 years ago when researchers used the serine phosphatase inhibitor 
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okadaic acid in skeletal muscle cells and 3T3-Ll adipocytes (51). Okadaic acid 
significantly diminished the effect of insulin on GLUT4 translocation and glucose 
transport in these respective tissues, by decreasing tyrosine phosphorylation on IRS-I, 
and downstream PI3-K activation. It was later discovered that okadaic acid specifically 
increases serine phosphorylation of IRS-l (39;49). It was shown that prolonged 
hyperinsulinemia in skeletal muscle cells and adipocytes also induce serine 
phosphorylation of IRS-I. This indicates that there may be a negative feedback 
mechanism in place that uncouples the IRS-l protein from its upstream/downstream 







Figure 5: Proposed mechanism of FF A-induced insulin resistance in skeletal muscle 
cells 
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In vitro L6 myotubes have often been employed to study the mechanism behind 
serine phosphorylation of IRS-I and skeletal muscle insulin resistance (52). This is 
because they are the best available in vitro skeletal muscle system, and are insulin 
responsive. However, these cells have a high basal serine phosphorylation of IRS-l 
protein when compared to intact human skeletal muscle (52). 
The increased serine phosphorylation of IRS-l is clearly linked to decreased 
tyrosine phosphorylation, leading to reduced glucose uptake (53). Many cytokines and 
protein kinases (as previously mentioned) not only induce serine phosphorylation ofIRS-
1 on its serine residue, but will simultaneously diminish insulin-induced tyrosine 
phosphorylation of IRS-I. Hyperphosphorylated IRS-Ion serine residues makes a poor 
substrate for the insulin receptor, thereby inhibiting its downstream effects. For example, 
diabetogenic stimuli may activate serine/threonine protein kinases or inactivate 
serine/threonine phosphatases, leading to increased serine phosphorylation of IRS-I, as 
seen in figure 5 and table 2 (37). In rodent models of obesity, inhibiting serine 
phosphorylation of IRS-l leads to increased insulin sensitivity in parallel with correction 
ofthe impaired insulin-induced tyrosine phosphorylation ofIRS-l (37;41;47;54). 
Several serine residues on IRS-l have been identified and linked to decreased 
insulin-stimulated IRS-l function and specifically IRS I-PI3K association, downstream 
Akt activation, and glucose uptake (39). Ser307 is located at the end of the phospho-
tyrosine binding (PTB) domain of IRS-I, which modulates the interaction of IRS-l with 
the insulin receptor (55). The association of IRS-l with the insulin receptor is 
significantly decreased once IRS-l becomes phosphorylated on ser307 by stimuli such as 
JNK, mTOR, p70 S6K, or FF A (39;55). In addition, it has been shown in vivo that 
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decreased phosphorylation at ser612 by MAPK correlates with enhanced insulin-
stimulated tyrosine phosphorylation of IRS-l (2). Similarly, the ser636/639 residues have 
been implicated in inhibiting IRS-l activity and are increased in rats fed a high fat diet in 
vivo (56). Finally, increased serl101 phosphorylation by PKce has been implicated in 
blocking IRS-1 tyrosine phosphorylation and downstream activation of Akt in C2C12 
skeletal muscle cells (43;57). Table 2 shows the various serine phosphorylation sites of 
IRS-l and how they regulate insulin signalling. 
Table 2: The known sites of IRS-I serine phosphorylation and the kinases involved 
Serine Residue Stimuli Tissue Effect on Insulin Signalling Reference 
307 FFA, okadaic acid, Muscle Decreased action Aguiree et al2000 (51) 
TNFo, mTOR, p70 Liver Gual et al2004 (37) 
S6K, JNK Fat Brustel et al 2003 (47) 
612 ERK, mTOR Muscle Decreased action Taniguchi et al 2006 (2) 
liver 
636/639 FFA, mTOR, p70 Muscle Decreased action Le Bo et al 2007(52) 
S6K liver Gual et al 2004 (37) 
Fat 
1101 PKCe, FFA Decreased action li et al2004 (41) 
Muscle Tremblay et al2007 (53) 
liver 
l.4c The GSK3 Pathway 
Glycogen synthase kinase-3 (GSK3) is a 51 kDa serine/threonine protein kinase 
that plays a role in the regulation of glycogen synthesis (40). GSK3 phosphorylates and 
inactivates glycogen synthase and is involved in the PI3-K/ Akt survival pathway (40). In 
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addition, GSK3 has been established to regulate glucose homeostasis and has been 
implicated in the development of insulin resistance (58). 
There are two different isoforms of GSK3, know as GSK3a and GSK3~ which 
have a high degree of homology in structure and biological function (59). Both isoforms 
of GSK3 have an inhibitory serine phosphorylation site (ser21 for a, and ser9 for ~), and a 
catalytic tyrosine activation site (Y279 for a, and Y216 for ~) (40). GSK3 is almost 
always constitutively active, and Akt or extracellular stimuli can induce serine 
phosphorylation of GSK3 to inhibit its activity (40). 
Studies in 3T3-Ll adipocytes has demonstrated that GSK3 increases senne 
phosphorylation of IRS-l and can attenuate the insulin-stimulated tyrosine 
phosphorylation on the insulin receptor and IRS-l (60;61). Furthermore, an association 
between GSK3 and insulin resistance has also been found in reported cases of type 2 
diabetes (58). The expression and activity of both GSK3a and GSK3~ is elevated in the 
skeletal muscle tissue of poorly controlled type 2 diabetic patients (58). In addition, there 
is an inverse relationship to insulin action and increased GSK3 levels in type 2 diabetic 
patients that underwent hyperinsulinemic/euglycemic clamp tests (58). Taken together, 
GSK3 is a key player in the modulation of glucose homeostasis, and may mediate the 
development of insulin resistance. 
l.4d Insulin Resistance and c-Jun N-terrninal Kinase (JNK) 
JNK is a serine/threonine kinase that is also known as stress activated protein 
kinase (SAPK), and is a member of the mitogen activated protein kinase (MAPK) family 
(54). There are three different isoforms in the JNK family, which are denoted JNKI 
(46kDa), JNK2 (54kDA), and JNK3 (54kDA). Of these members, JNKI and JNK2 are 
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ubiquitously expressed, whereas JNK3 is expressed mainly in the heart, testis, and the 
brain (54). JNKI is the isoform that has been speculated to playa role in the pathology 
behind obesity and insulin resistance. When activated, JNK forms a dimer that can 
translocate into the nucleus where it regulates the expression and phosphorylation of 
transcription factors such as c-lun, which in tum modulate gene transcription (42). 
JNK, can be activated by many environmental stresses, such as radiation, growth 
factors, cytokines like tumor necrosis factor alpha (TNFu) or interleukin-l J3 (IL-l (3), and 
elevated FFA (54). There is evidence found in high fat fed or genetic knockout mice 
models that implicate JNK as a mediator of insulin resistance (62). It was previously 
demonstrated that rats fed a diet high in saturated fat have increased JNK activity. This 
increase in JNK activation was correlated with ser307 phosphorylation of IRS-l in liver 
and skeletal muscle (54). These results were compared to rats fed a control diet for 10 or 
30 days, with insulin resistance being confirmed by hyperinsulinemic-euglycemic clamp 
procedures in both hepatic and skeletal muscle tissue. Only the rats that had developed 
insulin resistance by being fed a high fat diet showed increased JNK phosphorylation. 
Also, it has been recently demonstrated that JNK-interacting protein I (lIPl), 
which binds components of the JNK signalling pathway, is required for JNK activation 
and inhibition of IRS function in adipose tissue of obese mice (39). In epididymal fat 
pads from JIP I-deficient mice, insulin-stimulated tyrosine phosphorylation of IRS-l was 
increased and the inhibitory phosphorylation of IRS-Ion ser307 residue was decreased 
(39). Moreover, sustained activation of JNK was seen in primary mouse hepatocytes and 
pancreatic J3-cells of fat diet-induced insulin resistant mice and streptozotocin (STZ)-
induced diabetic mice. Conversely, mice with a targeted mutation at the JNKI locus that 
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abolished JNK expression, proved to be resistant to high fat-induced insulin resistance 
(62). The study by Solinas et al 2006, was in adherence with previous findings, in that the 
major mechanism behind JNK-mediated insulin resistance is through the ser307 
phosphorylation ofIRS-l (55). 
Studies have also addressed the different roles between JNKI and JNK2 in 
mediating high fat diet-induced insulin resistance and obesity in mice (54). It has been 
well documented that JNKl-/- or JNKI mutant mice have improved insulin sensitivity 
and protection from high fat diet-induced insulin resistance in liver tissue. Because 
JNK2-/- mice did not experience any significant changes in insulin sensitivity, JNK2 was 
ruled out as a key regulator in obesity and type 2 diabetes (42) Interestingly, JNK2 but 
not JNKI deficiency has been reported to provide protection against atherosclerosis and 
type 1 diabetes in mice. Thus, both isoforms of JNK playa role in mediating some aspect 
of the diabetes pathology. Furthermore, studies in vitro have shown that JNKI and JNK2 
exhibit similar affinity and activity towards ser307 phosphorylation of IRS-l in HEK293T 
hepatocyte cells (42). 
Antidiabetic medication such as rosiglitazone has been shown to inhibit JNK 
activation in vivo, and normalizes blood glucose homeostasis in insulin resistant mice 
(63). High fat diet-induced obese mice that were given rosiglitazone demonstrated 
marked JNK inhibition and reduced insulin resistance (64). Furthermore, JNK is involved 
in the apoptosis of pancreatic ~-cells induced by the IL-l ~ cytokine, which is prevented 
by its inhibition through rosiglitazone treatment (63). Given that the phosphorylation of 
JNK is increased in various insulin resistant models as previously mentioned, it is likely 
that this protein kinase is involved in mediating insulin resistance. 
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1.4e Protein Kinase C (PKC) and Insulin Resistance in Skeletal Muscle 
The PKC's are part of a large family of protein serine/threonine kinases consisting 
of ~10 isoforms that are divided into 3 subfamilies. Together, PKC's regulate a wide 
range of cellular processes, such as cell growth and differentiation, and participate in 
several signalling cascades (65). 
The different PKC isoforms have been divided into 3 subfamilies based on the 
substrates required for their activation (65). These groups are: the conventional calcium 
and diacylglycerol-dependent PKC's (cPKC, a, ~I-II, and y), novel calcium-independent 
PKC's (nPKC, 0, e, TJ, and e), and atypical calcium and diacylglycerol-independent 
PKC's (aPKC, S and t/A,) (66). 
Studies in L6 skeletal muscle cells have shown that high levels of the saturated 
FFA palmitate induced insulin resistance, which was correlated with a 5-fold increase in 
PKCs activity (35). However, in the presence of Ro 31.8220, a PKC inhibitor the 
palmitate-induced insulin resistance was attenuated (35). Furthermore, PKce has been 
reported to phosphorylate IRS-Ion serl101 , preventing downstream insulin signalling in 
C2C12 skeletal muscle cells and 3T3-Ll adipocytes (43). In addition, studies have shown 
that there is a link between FFA-induced insulin resistance and increased PCK activity in 
vivo (66). Lipid infusions in rats and humans impaired insulin-stimulated glucose 
disposal in skeletal muscle, as well as promoted increased activation of PKce and PKCo 
(67). Taken together, FF A potently increases PKC activity, which may mediate insulin 
resistance in skeletal muscle and fat tissue. 
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tAf IKKI NFKP Pathway and Insulin Resistance in Skeletal Muscle: 
NFK~ is a family of transcription factors that regulate the expression of many 
genes including pro-inflammatory genes. The NFK~ proteins consist of five members, 
which include p65, p50, RelB, and c-Rel. Dimerization of two NFK~ family members is 
necessary for it to bind to DNA, and induce transcriptional modification in the cell. In 
skeletal muscle, the predominant activating NFK~ dimer is the p50-p65 heterodimer (44). 
NFK~ is predominantly found in the cytoplasm, where it is associated with its respective 
inhibitory protein inhibitor of kappa ~ (IK~). Numerous stimulants, including cytokines, 
reactive oxygen species (ROS), hyperglycemia, and FF A, can activate IK~ kinase (IKK), 
which is upstream of IK~. Once IKK becomes activated it causes rapid IK~ 
phosphorylation, which leads to IKB dissociation from NFK~, and IK~ polyubiquitination 
and degradation by proteosomes located in the cytoplasm (44). This event allows NFK~ 
to be liberated from IK~ inhibition, which is now free to enter the nucleus and stimulate 
transcription of genes, as seen in figure 6. 
The IK~ gene family mediating NFK~ inhibition includes seven members IKpa, 
IKB~, IKB8, IKBy, Bcl-3, the precursor ReI proteins plOO, and plOS. Of these members 
IKBa and IKB~ are the subunits of IK~ that interact with NFKP and inhibit its DNA-
binding (44). IKBy acts as the regulatory subunit in the IKPI NFK~ inhibitor complex. 
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Figure 6: The various stimuli that regulate the NFK~ pathway 
Studies in L6 skeletal muscle cells have shown that palmitate-induced insulin 
resistance is mediated by NFK~ (34). In the presence of SN50, a peptide inhibitor of 
NFK~, the decrease in insulin-stimulated glucose uptake in L6 myotubes was attenuated 
(34). In addition, evidence collected from individuals with diabetes have suggested that 
the IKKJNFK~ inflammatory pathway is altered in patients with type 2 diabetes, and 
maybe responsible for the molecular mechanism causing skeletal muscle insulin 
resistance (44). Studies have shown that vastus lateralis muscle samples from patients 
with diabetes have a 60% decrease in IKB~ protein expression, when compared to 
matched control subjects, indicating increased NFK~ activity (44). Furthermore, increased 
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activation of IKK is linked to increased TNFa. expression in skeletal muscle and adipose 
tissue (44). TNFa. causes decreased glucose uptake and GLUT4 translocation to the 
plasma membrane in primary rat muscle cells, by impairing insulin stimulation of the 
insulin receptor and IRS-l/PI3-K association (68). 
Exercise training increases insulin sensitivity and some of the benefits of exercise 
may be due to its effects on the NFK~ pathway. Exercise training in patients with diabetes 
resulted in a 50% increase in IKBa. and IKB~ protein, and a 40% decrease in TNFa. 
production (44). Additionally, exercise training has also been shown to inhibit NFK~ 
activation (64) . These finding indicate that the IKKlNFK~ pathway plays a role in 
mediating insulin resistance, and the benefits of physical activity in individuals with 
diabetes is due to the modulation ofthis pathway. 
There are also reports that administration of an inhibitor of IKK, aspmn 
(salicylate) in patients with type 2 diabetes resulted in significant reduction of blood 
glucose levels, indicating that IKK is a key player in mediating insulin resistance (69). As 
such, future drug therapies that target IKK inhibition and the NFK~ pathway may provide 
significant improvements for regulating blood glucose levels in subjects with diabetes. 
1.4g mTOR and p70 S6K Pathway and Insulin Resistance in Skeletal Muscle 
The mammalian target ofrapamycin (mTOR), also known as RAFT! or FRAP is 
a 289 kDa serine/threonine kinase whose activation is increased by both nutritional 
(amino acids) and hormonal (insulin) factors (70). This kinase also plays a key role in cell 
growth and nutritional homeostasis, and may be abnormally regulated in tumors (71). 
Furthermore, mTOR is the mammalian counterpart of Saccharomyces cerevisiae TORI 
and TOR2, which is a member of the PI3-K-related family of proteins, that contains a C-
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terminal lipid kinase domain and is a downstream effector of Akt (70;72). mTOR exists 
as two different complexes, a rapamycin-sensitive complex, with the regulatory-
associated protein of mTOR (raptor) (TORC1), and a rapamycin-resistant complex with 
rapamycin-insensitive companion ofmTOR (rictor) (TORC2) (73). 
The signalling between Akt and mTOR involves the tuberous sclerosis complex 
(TSC), which consists of TSC1 and TSC2, and Rheb-GTP (a member of the Ras family) 
(70). Rheb has intrinsic GTPase activity and is able bind to both GDP and GTP. Both 
conformations of Rheb may directly bind to mTOR to modulate its activity (74). In the 
GTP-bound form Rheb increases mTOR activity. This process is mediated when Akt 
becomes phosphorylated, which will subsequently inactivate TSC and drive the intrinsic 
GTPase activity of Rheb towards the GTP-bound conformation (74). Conversely, in the 
GDP-bound form Rheb represses mTOR activity (70;74). This is achieved by increased 
TSC activity through the phosphorylation of AMPK, which drives the intrinsic GTPase 
activity ofRheb towards the GDP-bound conformation (75). 
mTOR may be phosphorylated on different serine residues to increase its activity. 
For example, the PI3-KlAkt signaling pathway phosphorylates mTOR on the Ser448 
residue, which enhances its activity. Similarly, mTOR may become autophosphorylated 
at the Ser481 residue, leading to its activation (71). Different subunits ofTORC1, such as 
PRAS40 (praline-rich Akt substrate 40) are required for full mTOR activation (74). 
Recent studies by Vander Haar et al, 2007 has demonstrated that activation of mTOR 
through Akt is dependent on proline rich Akt substrate (PRAS40) (76). Inhibition of 
mTOR is dependent on the interaction ofPRAS40 with mTOR on its kinase domain. This 
was observed in modified 293T cells that had a constitutively active mutant of mTOR 
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that was suppressed in the presence of PRAS40 (76). Conversely, mTOR is negatively 
regulated by AMPK, through at least two independent mechanisms (74). AMPK may 
phosphorylate TSC2 on multiple residues, which increases TSC2 activation (75). 
Secondly, AMPK can directly phosphorylate mTOR to decrease its kinase activity (75). 
mTOR has a downstream effector known as p70 S6K, which is a mitogen 
activated, 70 kDa serine/threonine kinase that plays a role in regulating the translation of 
a class of mRNA transcripts which contain an oligopyrimidine tract at their 
transcriptional start sequence (77). This class of mRNA transcripts encodes several of the 
mechanisms for the protein synthetic . apparatus, and may represent up to 20% of all 
cellular mRNA (77). This is accomplished when activated p70 S6K phosphorylates the 
40S ribosomal subunit protein S6, thereby promoting the translation ofmRNAs (47). p70 
S6K is believed to be regulated through mTOR activation. The TORCl complex induces 
phosphorylation of p70 S6K and the translation inhibitor factor eukaryotic translation 
initiation factor 4E binding protein (4EBPl) (73). In addition, p70 S6K is also negatively 
regulated by AMPK, which inhibit its activation by preventing phosphorylation of its 
upstream activator mTOR (78). 
Activation of the mTOR and p70 S6K pathway by increased amino acid levels 
has been shown to desensitize insulin's action in L6 myotubes and 3T3-Ll adipocytes 
through a mechanism that involves increased serine phosphorylation of IRS-l (79). 
Indeed, the activity of mTOR and p70 S6K are increased in the liver and skeletal muscle 
of rats that are fed a high fat diet, indicating that this signalling pathway may playa role 
in inducing insulin resistance in vivo (56). In vitro the effect of mTOR-induced insulin 
resistance is largely reversed using the mTOR inhibitor rapamycin. Rapamycin 
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specifically inhibits mTOR by interacting with the FKBP-rapamycin binding pocket of 
TOR, adjacent to the catalytic site of the kinase (72). Studies using insulin resistant 3T3-
LI adipocytes exhibited enhanced insulin-stimulated 2-eH]deoxy-D-glucose uptake 
when pretreated with rapamycin, suggesting that mTOR plays a role in down regulating 
the insulin signaling cascade (SO). Also, rapamycin administration in mice decreased 
serine phosphorylation of IRS-I and prolonged insulin-stimulated PI3-K activity in 
skeletal muscle (57). 
Recently Mordier et aI, 2007 showed that the FF A palmitate increased the 
phosphorylation of mTOR in rat hepatocytes (45). Palmitate-treated cells exhibited a 
rightward shift of the insulin dose-response curve for Akt phosphorylation, indicating 
insulin resistance. Additionally, hepatocytes incubated with palmitate (O.4mM) for 22h 
displayed hyperphosphorylation of IRS-I at serine residues 632/639, thereby inhibiting 
downstream insulin signalling (45). Other in vitro studies in skeletal muscle cells and 
adipocytes demonstrate that amino acids induced phosphorylation of mTOR and reduced 
insulin-stimulated tyrosine phosphorylation of IRS-I and decreased the activity of PI3-K 
(S1). 
Directly downstream from mTOR, p70 S6K (S6KI) has also recently been 
implicated in inhibiting normal insulin signaling in skeletal muscle and adipose tissue 
(72). In vitro studies have shown that treatment with S6KI siRNA significantly increased 
insulin-stimulated Akt phosphorylation and increased insulin sensitivity in MEF mouse 
embryonic fibroblast cells (S2). In addition, knockout mice that have a S6KI deletion 
exhibit decreased IRS-I phosphorylation on ser307 and ser636/639 when subjected to a high 
fat diet, compared to their wild-type counterparts (56). Thomas et aI, 2004 has also 
Attenuation of skeletal muscle insulin resistance by resveratrol 30 
demonstrated that S6Kl-deficient mice are protected from obesity when subjected to a 
high fat fed diet (47). Conversely, elevated S6Kl has been correlated with decreased Akt 
activity in obese insulin-resistant rodents (47). Further insight into the molecular 
mechanism linking S6Kl to serine phosphorylation of IRS-I was seen by studies 
involving the disruption of the TSC 1-TSC2 tumor suppressor complex (57). Inhibition of 
this complex in mouse embryonic fibroblasts causes ser!! 01 phosphorylation of IRS-I and 
degradation, as well as inhibition ofIRS-I transcription (57). Moreover, S6Kl was found 
to be constitutively active in TSC 1-TSC2-deficient skeletal muscle cells (57). 
The mTOR and p70 S6K pathway regulates insulin-stimulated glucose uptake 
through a negative feedback mechanism. Once blood glucose homeostasis is achieved, 
mTOR and p70 S6K inhibits the insulin signal by ser307 and ser636/639 phosphorylation of 
IRS-I. However, chronic activation of the mTOR and p70 S6K pathway through various 
stimuli (as mentioned earlier) may cause insulin resistance in skeletal muscle, liver, and 
adipose tissue. 
1.4h Free Fatty Acids (FFA) Induce Insulin Resistance in Skeletal Muscle 
Non-esterified fatty acids (NEF A) play an important role in the establishment of 
insulin resistance and type 2 diabetes (49). Studies using NMR spectroscopy 
demonstrated a strong relationship between the accumulation of intrarnyocellular 
triglyceride content and skeletal muscle insulin resistance (83;84). This relationship is 
believed to be explained by the Randle hypothesis, whereby FF A compete with glucose 
for substrate oxidation and that elevated fat oxidation mediates the insulin resistance 
associated with obesity (85). Randle proposed that increased FF A concentration leads to 
increased mitochondrial acetylCoAiCoA and NADHINAD+ ratios, which subsequently 
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inhibit pyruvate dehydrogenase activity and cause increased citrate levels that inhibits 
phosphofructokinase activity (85). 
In addition, it has been reported that increased FF A exposure in skeletal muscle 
cells inhibits downstream insulin-stimulated Akt phosphorylation. This inhibition has 
been linked to an increase in ceramide concentration from fatty acyl-CoA metabolism 
(49). The increase in cerami de may then in turn, activate a series of phosphatases such as 
phoshatase 2A that will dephosphorylate Akt. Thus Akt remains inactive in the presence 
of FF A, diminishing the insulin-stimulated glucose uptake response in skeletal muscle. 
Furthermore, studies have examined the effect of saturated fatty acids on glucose 
uptake in skeletal muscle cells (86). Dimopoulos et aI, 2006 has shown that L6 skeletal 
muscle cells that were incubated with palmitate at a concentration of 0.75mM for 16 
hours, demonstrated a significant decrease in GLUT4 translocation to the plasma 
membrane (86). This reduction in GLUT4 translocation was correlated to the decrease in 
glucose uptake observed in these muscle cells. 
Additionally, increasing FF A levels in rats by an intralipid infusion resulted in an 
twofold increase in ser307 phosphorylation of IRS-l and a decrease in insulin sensitivity 
(87). Elevated FF A in overweight individuals may explain their greater risk of 
deVeloping insulin resistance and type 2 diabetes (36). Insulin resistance is associated 
with the accumulation of intramyocellular lipids, which in itself do not appear to cause 
insulin resistance. However, they are markers for other lipid intermediates such as fatty 
acyl-CoA, cerami des or diacylglycerols, which can directly alter the insulin signalling 
cascade (36). A summary of the various kinases implicated in mediating insulin 
resistance through serine phosphorylation of IRS-l is shown in figure 7. 
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Figure 7: Serine phosphorylation of IRS-I and potential stimuli involved in regulating 
the activity of IRS-I 
1.5 AMP-activated Protein Kinase Pathway 
AMPK is a 62 kDa serine/threonine kinase that plays a key role in the regulation 
of energy balance in the cell. AMPK is activated in response to an increase in the 
AMP/ ATP ratio. A reduction in ATP levels as a function of increased muscle activity 
leads to activation of AMPK, which phosphorylates and inhibits acetyl-CoA carboxylase 
(ACC). This inhibition causes a decrease in the levels of malonyl-CoA, which itself is a 
potent inhibitor of carnitine palmitoyltransferase I (CPT I) (88). The loss of CPT 1 
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inhibition will promote enhanced beta-oxidation of fatty acid in muscle mitochondria, 
which in turn replenishes ATP levels (89). 
Structurally, AMPK exists as a heterotrimer containing a catalytic a subunit and 
regulatory ~ and y subunits (90). Presently, homologues of each AMPK subunit have 
been identified in every eukaryotic species, ranging from fruit-flies, worms, and yeast, to 
fish and mammals (91). AMPK is also related to a protein kinase complex in 
Saccharomyces cerevisiae termed SNFI, and shares similar structure and function (91). 
In mammals the following isoforms of the different AMPK subunits exist aI, a2, ~1, ~2, 
Y 1, y2, and y3 (89). 
The N-terminal section of the a subunit of AMPK contains the serine/threonine 
kinase catalytic domain. In addition, this subunit of AMPK contains the thrl72 residue, 
which becomes phosphorylated and is essential for AMPK activation. On the other hand, 
the C-terminal segment of the a subunit of AMPK is required for association with the ~ 
and y subunits (92). The physiological function of both the ~ subunit and y subunit of 
AMPK has not been widely studied. However it has been reported that the ~ subunit acts 
as a scaffold to link the a and y subunits of AMPK together. The y subunit has been 
shown to playa role in glucose metabolism and fat oxidation (93). 
AMPK phosphorylation and activation is regulated by the upstream protein 
kinases LKBI (91), calcium/calmodulin-dependent protein kinase (CaMKK), and TGF~­
activated kinase-l (TAKI), and by SIRTI (94). LKBI is a tumor suppressor that 
phosphorylates the thrl72 residue of AMPK to promote its activation (91). Studies have 
demonstrated that AMPK activation is abolished in human fibroblast cells lacking 
expression ofLKBI, or following inhibition ofLKBI (95;96). Similarly, phosphorylation 
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of AMPK is prevented in L6 skeletal muscle cells in the presence ofSTO-609, a CaMKK 
inhibitor (97). Furthermore, in mice embryos that expressed a TAKl-knockout, 
pharmacological activation of AMPK by AICAR (5-amino 4-imidazolecarboximide 
riboside) and metformin was completely abolished (98). Also, recent evidence has shown 
that in the presence of splitomicin, a SIRTI inhibitor, activation of AMPK by the 
polyphenol resveratrol was inhibited (94). 
There are many reports that AMPK acts to increase glucose uptake in skeletal 
muscle cells. Studies using L6 and C2C12 skeletal muscle cells in vitro have shown that 
AMPK activation by resveratrol increases glucose uptake. Conversely, inhibition of 
AMPK by the AMPK inhibitor compound C prevents resveratrol-stimulated glucose 
uptake (99; 1 00). In addition, studies in vivo have demonstrated that transgenic animal 
that exhibited a deletion in AMPK a2 catalytic subunit experienced insulin resistance and 
decreased insulin secretion (101). Taken together, these funding suggest that AMPK is a 
key player in energy homeostasis and glucose uptake in skeletal muscle. 
THEPOLYPHENOLRESVERATROL 
1.6a Sources of Resveratrol 
Resveratrol (3,4' ,5-trihydroxy-trans-stilbene) IS a polyphenolic compound, 
classified under the stilbene class of polyphenols (102). Many stilbenes found in plants 
act as phytoalexins, which are compounds that are generated with the help of the enzyme 
stilbene synthase, and only in response to injury or infection (102). Stilbenoids are 
antibacterial and anti-fungal chemicals produced by plants as a defense against infection 
by invading pathogens. 
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Resveratrol is a widespread phytoalexin that can be found in at least 72 species of 
plants, spread over 31 genera and 12 families (103). It was first isolated in 1940 as a 
constituent of the white hellebore roots Veratrum grandiflorum. Presently, there are 
numerous dietary sources of resveratrol that range from raspberries, mulberries, plums, 
berries of Vaccinium species, including blueberries and cranberries, some pines, such as 
Scots pine and eastern white pine, and the roots and stalks of giant knotweed and 
Japanese knotweed, peanuts, cocao, and in the highest concentrations in red grape skin 
and red wine (103). On average, ordinary non-muscadine red wine contains between 0.2 
and 5.8 mg ofresveratrol per liter of wine, as seen in table 3 (104). Resveratrol content in 
white wine is much lower, due to the different ways that the wines are produced. Red 
wine is fermented with the skin still attached to the grape, which allows resveratrol 
absorption into wine. White wine is fermented after the skin has been removed from the 
grape, thereby lowering resveratrol content (105). 
The benefits received from dietary polyphenol consumption are not limited to 
today's western society. In the 1980's Japanese scientists observed that the dried roots of 
Polygonum cuspidatum have been utilized in traditional Japanese and Chinese medicine 
for hundreds of years. The medicinal product known as "Kojo-Kon" was used to treat a 
wide variety of aliments ranging from fungal diseases, skin inflammations, heart disease, 
and blood vessel obstructions (102). Resveratrol was the primary active ingredient in this 
herbal remedy, with its properties being further supported by present studies using in 
vitro and in vivo animal models. 
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Table 3: Dietary sources ofresveratrol (l05) 
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Content of Resveratrol in Food 
Food Serving (g) 
Peanuts (raw) 146 
Peanuts (boiled) 180 
Peanut Butter 258 
Red Grapes 160 
1.6b Chemical Structure of Resveratrol 













Although resveratrol is classified as a stilbene, it differs in the structure of classic 
stilbenes by containing three hydroxyl groups that participate in an extensive three 
dimensional hydrogen-bonding (H-bonds) network (106). These H-bonds may readily 
form and break H-bonds with other neighboring phenolic oxygen, thus explaining its 
antioxidant properties. The precursor for all stilbenes is phenylpropanoids, which include 
flavonoids, as well as resveratrol (106). The aromatic ring structure of resveratrol (figure 
7) allows it to bind with many different enzymes and receptors (107). 
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Resveratrol exists as two different isomers which are labeled cis, and trans (107). 
The primary source of resveratrol found in nature and in industry is the trans isomer, 
which is also the most biologically active form. Trans-resveratrol becomes isomerised to 
the cis isomer under exposure to light as shown in figure 8 (107). 
Cis- resveratrol is less biologically active that trans-resveratrol, demonstrating the 
difference in the molecular behavior of the two isomers, which is governed by their three-
dimensional molecular structure (106). For instance, resveratrol interacts with the 
estrogen receptor in a stereoselective manner. Studies of the two resveratrol isomers (cis, 
and trans-resveratrol) on MCF-7 breast cancer cells have demonstrated that the trans-
resveratrol isomer IS a much stronger mixed estrogen receptor-a (ER-a) 
agonist/antagonist than the cis-resveratrol isomer (107). Recent studies using molecular 
dynamics and docking experiments have demonstrated that trans-resveratrol has greater 
hydrogen bond interactions binding to the ER-a than the cis isomer, providing an 
explanation for the stereoselective ligand binding with the protein. 
OH 
Light 
Figure 8: Resveratrols isomerization by exposure to light. 
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1.6c Bioavailability of Resveratrol 
There are few studies that examined the bioavailability of resveratrol. The 
absorption of resveratrol in rats was first examined in 1996. Studies by Bertelli et ai, used 
red wine with established resveratrol content (6.5mg/L) to examine the bioavailability of 
resveratrol in male Wistar rats that were fed 4mL of red wine per day (equal to 86/lg/Kg 
of resveratrol), for 15 days (108). The results demonstrated that the resveratrol contained 
in wine was quickly absorbed, reaching its maximal blood concentration after 60 minutes 
of wine ingestion. After a very short period of time, resveratrol was detected in the liver 
and kidneys of rats. The kidney showed signs of decreased resveratrol concentration after 
1 hour, indicating that it may be the preferential organ of excretion (108). 
Studies by Marier et ai, in 2002 used a single oral dose of resveratrol in rats and 
examined its metabolism using electro spray ionization-liquid chromatography (108). Rats 
that were administered an oral dose of resveratrol (50 mg/kg body weight) experienced a 
rapid drop in serum levels of resveratrol within 8 minutes. However, detectable levels of 
resveratrol remained for 12 hours, due to enterohepatic recirculation from the liver (108). 
This study demonstrated that the bioavailablity of resveratrol undergoes extensive first-
pass glucuronation. This study also concluded that the terminal elimination half life of 
resveratrol is approximately 1.6 hours in rats (lOS). 
It wasn't until 2003 that the metabolism and bioavailability of resveratrol was 
studied in humans. Subjects were administered 10mg of resveratrol per 70Kg of body 
weight. Serum levels of resveratrol peaked at 1.S2/lM within 30 minuets of its ingestion, 
and took between 7-10 hours to excrete most of it in the urine (102). Although the 
resveratrol concentration being administered is fairly high in human studies, the 
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absorption of it is fairly low, with approximately 75% of it being excreted (102). The oral 
bioavailability of resveratrol is negligible due to rapid metabolism and the consequent 
formation of various metabolites as resveratrol glucuronides and sulfates (102). It was 
shown that the liver and kidney are the main targets of resveratrol uptake, as well as 
being key players in the absorption and bioavailability of many other dietary polyphenols 
(102). 
To increase the bioavailability of resveratrol, a study by Hung et aI, 2008 
demonstrated that resveratrol transported via the skin had lower metabolism and a 
prolonged half-life compared to oral administration (109). In addition, applying 
resveratrol to the skin also provides protection against UV exposure by the sun (109). 
Currently, there are several phase I clinical trials underway for oral administration of 
resveratrol in humans (109; 11 0). Some studies are providing an oral dose of resveratrol 
as high as 7.5g per day (109). 
1.6d Toxicity of Resveratrol 
In vitro, resveratrol is used in fairly high concentrations ranging from 1-100flM in 
various cells including vascular, cancer, and skeletal muscle (99). However, high 
concentrations of resveratrol over 100flM have been reported to have severe toxicity in 
C2C12 skeletal muscle cells (100). 
There are a few in vivo studies that have examined the toxicity of resveratrol in 
animals. A study by Juan et aI, 2002 administered resveratrol (20mg/Kg body weight) 
orally to rats for 4 weeks and reported no toxic effects (111). A single highly 
concentrated oral dose of resveratrol (2000mg/Kg body weight) did not have any 
detectable toxic effect in rats as well (111). However, it has been demonstrated that there 
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are toxic effects in rats administered 300-3000mg of resveratrol by gavage for 4 weeks 
(104). Clinical signs of toxicity included decreased body weight, reduced hemoglobin, 
increased white blood cell number, and increased kidney weight with associated 
nephropathy was observed in rats receiving 1000mg of resveratrol or more over the 
course of 4 weeks (104). In human subjects, resveratrol has a short half-life and there is 
no established toxic dose (109). 
1.6e Transport of Resveratrol through the Cell 
Resveratrol has low water solubility and thus, must be bound to proteins and/or 
conjugated to remain in high concentrations in serum (112). A study by Janin et al, 2004 
demonstrated that resveratrol interacts with lipoproteins of rat liver cells in vivo. 
Specifically, resveratrol was found to associate with albumin, which is well known to 
bind and carry a variety of other amphiphilic molecules (112). For example, it was shown 
that querectin, another polyphenolic compound, interacts with very high affinity with 
albumin in rat plasma and human serum albumin (113). In addition, a recent study by 
Walle et al, 2004 observed that only trace amounts «5 ng/mL) of unconjugated 
resveratrol was found in the plasma after administration of 25mg/ 14C-resveratrol to six 
healthy human subjects (114). 
In vitro assays also demonstrated that resveratrol added to plasma increased with 
increased lipoprotein content (115). The concentration of resveratrol in plasma increased 
with the order of the lipid content, i.e. HDL < LDL < VLDL, and that resveratrol is more 
aggregated with lipoproteins than with lipoprotein-free proteins. This binding occurs in 
vivo as well, since it is found in the presence of LDL isolated from blood samples of 
healthy individuals (115). 
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Studies using HepG2 cells in vitro have examined the kinetics of labeled 
resveratrol transport (116). The uptake of resveratrol in HepG2 cells involves both 
passive diffusion and a carrier-mediated process. Similar studies have examined the 
transport of resveratrol through human intestinal epithelial cell (Caco-2) (117). KaIdas et 
ai, 2003 demonstrated that resveratrol passively crosses the plasma membrane of Caco-2 
cells at a rapid, dose-dependent rate. Taken together, these studies suggest that resveratrol 
is quickly absorbed through a mechanism that may be passive or carrier-mediated. 
1.6f Biological Effects of Resveratrol 
Numerous in vitro and in vivo studies have demonstrated the different beneficial 
biological effects of resveratrol (99;118-120). Presently, it has been established that 
resveratrol possesses antioxidant (121), anticardiovascular diseases (120;122), anticancer 
(119), antiaging (118), and antidiabetic properties (99;118;123). In the following sections 
ail of the above mentioned biological effects ofresveratrol are reviewed. 
1.6g The Antioxidant Properties of Resveratrol 
Reactive oxygen species (ROS) are small molecules with unpaired valence shell 
electron that are highly reactive in biological tissue (124). ROS are generated as a natural 
byproduct of oxygen metabolism and play a critical role in cell signalling (125). 
Excessive ROS levels also termed oxidative stress may be due to increased production or 
decreased removal of ionizing radiation and other environmental factors that may result 
in increased ROS levels. The main ROS are the hydroxyl radical (OH), superoxide (02-), 
nitric oxide (NO·), and hydrogen peroxide (H202) (124). These ROS may activate 
signalling pathways such as JNK, PI3-KlAkt, and NFK~, which may lead to the 
modulation of genes and increased cell apoptosis (124). 
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It is suggested that the majority of intracellular ROS is derived from the 
mitochondria and is counterbalanced by an intricate antioxidant defense system (124) that 
include the enzymatic scavengers superoxide dismutase (SOD), and glutathione 
peroxidase that convert 02- into water (126). The body may also combat oxidative stress 
with antioxidants, compounds that stop oxidation of important cellular targets, and with 
free radical scavengers that act on free radicals to make them stable products. There are a 
variety of naturally occurring antioxidants found in fruits and vegetables, as well as 
synthetic ones created by the pharmaceutical industry (127). Figure 9 summarizes some 
of the events that may occur by ROS. 
Resveratrol is established to have antioxidant properties (121). Flavonoids and 
other polyphenols like resveratrol can donate hydrogens or interact with free radicals like 
superoxide and hydroxide ions. By doing so, resveratrol converts these free radicals into 
harmless, unreactive compounds in the body (128). For example, studies by Olas et aI, 
2001 have shown that resveratrol decreased free radical formation in platelets (129). 
Platelets in vitro were stressed, and ROS such as superoxide and hydrogen peroxide were 
measured usmg chemiluminescence. Resveratrol was shown to inhibit 
chemiluminescence and generation of ROS in these blood platelets, as well as the 
production of thrombin and thiobarbituric acid-reactive substances (TBARS) (129). 
Resveratrol is able to counteract oxidative damage caused by H202 in rat primary cortical 
astrocytes in vitro (126). 
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Environmental Stress, Radiation, Free Radicals 








Figure 9: The major signalling pathways effected in response to ROS 
Increased ROS levels lead to DNA damage and mutation. Studies in 
normal rat fibroblasts, mouse mammary epithelial cells, human breast, and human 
prostate cancer cells showed that resveratrol significantly reduces DNA fragmentation, as 
assessed by single cell gel electrophoresis (130). Resveratrol was shown to prevent 
increased ROS levels following exposure to oxidative agents like tobacco smoke (130). 
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In addition, resveratrol was shown to prevent oxidative stress in human lung fibroblasts 
by increasing mitochondrial superoxide dismutase (MnSOD) which, by itself is capable 
of reducing intracellular oxidative stress (131). 
1.6h Anti-cardiovascular Disease Properties of Resveratrol 
Interest in the study of polyphenolic compounds present in red wines has grown 
since epidemiological studies have observed a decrease in cardiovascular disease in 
individuals that frequently drink red wine (108). This observation was prominent in 
France, and also helped explain the "French paradox", which is the inverse relationship 
between the high consumption of fatty foods, and the low incidence of cardiovascular 
disease found in the French population (108). Resveratrol is able to inhibit the 
peroxidation of lipid membranes, to decrease the concentration of low (LDL) and very 
low (vLDL) density lipoproteins, and inhibit platelet aggregation (108). These three 
factors are all strongly linked to cardiovascular disease and stroke. Resveratrol may also 
decrease smooth muscle cell proliferation, and act as a vasorelaxing agent (132). 
Furthermore, there has been research that implicates resveratrol in having 
cardioprotective action directly on the heart. Studies by Liew et aI, 2005 have 
demonstrated that resveratrol exerts multiple direct actions on guinea-pig cardiac 
myocytes (133). Resveratrol significantly decreased the duration of action potentials, as 
well as peak L-type calcium (Ca2+) currents. This suggests that acute treatment with 
resveratrol increases Ca2+ sensitivity in cardiac myocytes and thereby reduces cardiac 
stress (133). 
Studies have also investigated the potential cardio protective effects of resveratrol 
on the diabetic heart. For example, Dekkers et aI, 2007 used normal and diabetic rats that 
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were orally fed resveratrol (2.5mg/Kg/day) for 1 week to examine myocardial infarct size 
and cardiomyocyte apoptosis upon global ischemia in isolated rat hearts (134). They 
found that resveratrol decreased infarct size and apoptotic cell death in both normal and 
diabetic rat groups. The ability of resveratrol to mediate these cardio protective effects 
was attributed to the modulation of several stress proteins such as heat shock protein 27 
(HSP 27) and a~-crystallin (134). Similar results were found by Aubin et aI, 2008 in 
normal female rats fed a ·high fat diet for 8 weeks (135). These rats become obese and 
diabetic by the end of the 8 week period. A significant increase in systolic and diastolic 
blood pressure, as well as decreased acetylcholine-dependent relaxation of the aortic ring 
was seen in rats fed a high fat diet. However, administration of resveratrol (20mg/Kg/day) 
for 8 weeks significantly prevented these high fat diet-induced effects (135). More 
recently, a study by Lekli et aI, 2008 attempted to investigate if resveratrol could improve 
postischemic cardiac function, infarct size, and arrhythmias in Zucker obese rats (136). 
After 14 days of resveratrol treatment (5mg/Kg), postischemic cardiac function was 
improved and the incidence of ventricular fibrillation and infarct size was reduced by 
83% (136). Furthermore, they discovered that resveratrol increased GLUT4 expression 
and decreased endothelin expression and cardiac apoptosis in ischemic-reperfused hearts 
in the presence or absence of glucose intake (136). 
1.6i Anticancer Properties of Resveratrol 
The link between resveratrol and cancer prevention has been widely studied in the 
cancer field. Tumorigenesis is classified into three major stages; cancer initiation, 
promotion, and progression (119). Resveratrol has been established to have 
chemopreventive cancer proprieties, and can inhibit all three stages of cancer cell 
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progression (119). Resveratrol has also been shown to suppress the proliferation of a 
wide variety of tumor cells, including lymphoid, myeloid, multiple myeloma, prostate, 
stomach, colon, pancreatic, thyroid, melanoma head and neck squamous cell carcinoma; 
ovarian carcinoma, and cervical carcinoma (119). The anticancer effects of resveratrol 
are due to cell-cycle arrest, increased expression of protooncogenes (such as p21, and 
p53), and down-regulation of cancer cell survival. Resveratrol is known to suppress 
several transcription factors including, NF -kappa ~ (NF1(~), AP-l, Egr-l, and to inhibit 
protein kinases involved in cell survival, such as Akt, JNK, MAPK, and PKC (119). 
Studies using androgen-insensitive prostate cancer cells has shown that 
resveratrol downregulates many of the genes involved in prostate cancer cell survival 
(137). In addition, resveratrol upregulates the expression of TNF-related apoptosis 
inducing ligands (TRAIL), thereby arresting prostate cancer development. Also, the 
combination of resveratrol and TRAIL enhanced the mitochondrial dysfunctions during 
cell apoptosis (137). 
In addition, resveratrol has the ability to induce s-phase arrest in several human 
cancer cell lines. Studies by Joe et aI, 2002 has examined the effects of resveratrol on six 
different human cancer cell lines, MCF7, SW480, HCE7, Seg-l, Bic-l, and HL60 (138). 
In five of these cancer cell lines, resveratrol induced significant growth inhibition with an 
ICso value of 70-150/lM. Also, following treatment with 300/lM resveratrol, most of the 
cell lines were arrested in the S phase of the cell cycle (138). Resveratrol treatment for 2 
days demonstrated significant reduction in cyclin B 1 expression levels in all cancer cell 
lines, indicating that the cancer cell is not progressing through the cell cycle. Another 
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study by Ginkel et aI, 2008 observed that resveratrol has the ability to inhibit uveal 
melanoma tumor growth in vitro and in vivo (139). 
Recently a study by Schlachterman et aI, 2008 demonstrated that resveratrol, in 
combination with other grape polyphenols, decreased the size of primary breast cancer 
tumors in nude mice (140).Peak brest cancer inhibition was observed using in situ image 
analysis at 5mg/Kg of resveratrol. Similar results were reported by Garvin et aI, 2006 
where resveratrol significantly inhibited brest cancer tumor growth and increased cancer 
cell apoptosis in nude mice (141). 
1.6j The Prosurvival and Anti-Aging Properties of Resveratrol 
Initial studies showed that caloric restriction in yeast resulted in cell survival and 
increased lifespan by increased activity of sir2 (142). Moreover, resveratrol is a potent 
activator of sir2 and its mammalian counterpart SIRTI (142). Enhanced activation ofSir2 
by resveratrol in the nematode Caenorhabditis elegans and the fruit fly Drosophila 
melanogaster has also been linked to lifespan extension through a dietary restriction-like 
mechanism (143). Recently, it has been established that resveratrol has the ability to 
prolong the survival of mice on a high fat diet (118;144). 
However, the mechanism of action of resveratrol to increase lifespan through Sir2 
activity has been variable. Studies have also reported that resveratrol may not extend the 
lifespan of nematodes or fruit flies, or that it may do so through the interaction with other 
proteins that have yeast homologs, such as AMPK and protein kinase C (145;146). In 
addition, increased lifespan does not imply enhanced Sir2 activity, as several single-gene 
mutations are know to extend the lifespan of yeast in a Sir2-independent manner (146). 
Furthermore, in vitro assay has shown that resveratrol activates Sir2 to deacetylate a 
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fluorescent peptide substrate, it does not activate either Sir2 or the human ortholog SIRTI 
towards more native peptide substrates (147). More recently, a study by Bass et al, 2007 
has reported that their result on lifespan extension using resveratrol treatments on C 
elegans and D melanogaster has been inconsistent (145). 
Taken together, resveratrol has been shown to have pro survival proprieties 
through the activation of sirtuins. However, there are some reports that indicate 
resveratrol may prolong lifespan through different mechanisms. 
1.6k The Sirtuin Family of Histone Deacetylases and Anti-Aging 
Histone deacetylases (HDAC) are a class of enzymes that playa role in removing 
acetyl groups from an N-acetyllysine amino acid or histones (148). Activation of HDAC 
causes hypoacetylation of histones, resulting in a stronger association between the 
nucleosome and the DNA wrapped around it (148). Thus, the tighter the association 
between the DNA and nucleosome the less chance transcription factors can access the 
DNA, thereby causing transcriptional repression (149). 
The family of HDACs consists of 3 subclasses; RPD3 (class' 1), HDA 1 (class II), 
and sir2 (class III) (150). Class I and II of HDACs use zinc as cofactors to deacetylate 
substrates and are inhibited by trichostatin (TSA) (151). The class III of HDACs (group 
III) differs in that; they require nicotinamide adenine dinucleotide (NAD+) as a cofactor 
to deacetylate substrates and are inhibited by nicotinamide, splitomicin, and sirtinol 
(150;151). In addition, HDAC's are characterized by a domain of approximately 260 
amino acids that have a high degree of structural similarity (152). 
The sirtuins are class III histone and protein deacetylases (HDACs) that were 
named after their homology to the Saccharomyces cervisiae gene silent information 
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regulator 2 (Sir2) (150). There are seven mammalian homo logs of sirtuins (SIRTl-7) 
(151). In yeast, Sir2 has been reported to mediate global metabolic changes and life span 
extension (153). The mammalian homologs of Sir2 have been shown to regulate many 
important biological process ranging from life span extension, to apoptosis, energy 
metabolism, muscle differentiation, and gluconeogenesis (150). In the following sections 
a review of the localization and function of the sirtuin family will be presented. 
Sir2 involvement in life span extension: Initially it was demonstrated that 
caloric restriction (CR) can significantly increase the life span of Saccharomyces 
cerevisiae (yeast) by causing metabolic changes (154). The identification of sir2 as a 
potential molecular mediator of CR is a breakthrough in understanding the molecular 
mechanism underlying the process of aging. sir2 in yeast is a nuclear protein that can 
deacetylate histones, bind to telomeres, and induce transcriptional repression of the silent 
mating type loci; such as homothallic mating-type loci left (HML) to promote cell 
longevity. The aging of yeast can be mediated by the accumulation of extrachromosomal 
rDNA circles (ERCs) in the nucleus, which sir2 can inhibit (153). Studies that used 
deletions of sir2 in yeast demonstrate a dramatic increase in ERC formation, while 
shorting life span by approximately 50% (153). Conversely, studies that use 
overexpression of sir2 in yeast show decreased ERC expreSSIOn, decreased histone 
acetylation, and an increase in life span by 30-40% (153). 
In Caenorhabditis eiegans, the yeast sir2p ortholog, sir2.1, extends life span via 
the forkhead (FOXO) transcription factor Daf-16 signalling pathway (150). This pathway 
is responsible for the early development states of growth arrest that is induced upon food 
limitation in nematode larva. Studies that duplicated the chromosomal regions containing 
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sir2.1 in the nematode extended its life span by up to 50% (155). Conversely, nematodes 
containing a mutated Daf-16 gene displayed a significant decrease in life span compared 
to wildtype nematodes. 
In Drosophila melanogaster, the sir2 ortholog, dsir2 regulates life span extension 
under CR conditions (150). The ability of dsir2 to mediate life span extension is believed 
to be through the same pathway as Rpd3 histone deacetylase, given that Rpd3 is thought 
to negatively regulate dsir2, and CR induces a decrease in Rpd3 expression (150). 
Mutations in dsir2 have been shown to inhibit the CR-mediated increase in life span seen 
in flies (156). Furthermore, long-lived Rpd3 mutant flies demonstrate increased dsir2 
expression levels that correlate with increase longevity (156). 
The mammalian SIRTl-7: The mammalian NAD+ pathway is different from the 
yeast NAD+ pathway in that, nicotinamide adenine mononucleotide (NAM) is directly 
converted to nicotinamide mononucleotide (NMN) by the enzyme nicotinamide 
phosphoribosyltransferase (NamPT) (150). The functions of each of the NAD+-dependent 
sirtuins (1-7) may vary in a tissue-specific manner. SIRTI is the most widely studied of 
all the mammalian sirtuins. 
SIRTl: SIRTI is a 120 kDa HDAC that is localized in the nucleus and cytoplasm 
(154). There have been an increasing number of studies focusing on the beneficial effects 
of SIRTI activity in the amelioration of metabolic diseases such as type 2 diabetes (144). 
For example, studies have demonstrated that SIRTI can augment insulin secretion in 
response to glucose in the ~-cells of the pancreas (157). Moynihan et aI, 2005 showed 
that beta cell-specific SIRTI-overexpressing (BESTO) transgenic mice had decreased 
expression of uncoupling protein 2 (UCP-2), which impedes H+ leakage to allow more 
Attenuation of skeletal muscle insulin resistance by resveratrol 51 
efficient coupling of electron transport (157). This in turn provides improved glucose 
tolerance and enhanced insulin secretion in the pancreatic ~-cells. 
Resveratrol has been used in numerous studies investigating the role of SIRTI 
activation in mammalian tissues. Several studies implicate resveratrol in improving 
health and extend maximum lifespan of vertebrate fish by 59% in a SIRTI-dependent 
fashion (118;158). More recently, resveratrol was proposed to extend the lifespan of mice 
by 20% via SIRTI activation (118). 
A possible mechanism in which resveratrol interact with SIRTI has been shown 
using a covalently attached flurophore, and 7-amino-4-methylcoumarin (p53-AMC) 
peptide (147). Resveratrol is able to bind to SIRTI and causes a conformational change 
. 
that better accommodates the attachment of SIRTI-substrates, such as p53 (147). SIRTI 
has several residues such as Gln102, MetlO\ PhelO5 , and Arg254 that likely interact with 
resveratrol once it is bound (147). The current hypothesis in resveratrol-mediated SIRTI 
activation is via a single allosteric site on the SIRTI-substrate complex, to which 
structurally diverse compounds can bind (144). This theory is supported by Milne et al, 
2007 who demonstrated that structurally diverse small molecule activators, unrelated to 
resveratrol activated SIRTI up to 1000-fold more potent than resveratrol alone (144). 
Furthermore, all of the SIRTI activators share the same allosteric compound binding site 
on amino acids 240-664, as well as the amino acids 183-225 N-terminal to the core 
SIRTI domain (144). 
SIRTI has been reported to deacetylate many different molecules/substrates. For 
example, in the liver SIRTI forms a substrate-complex with hepatocyte nuclear factor-4 
(HNF-4) to deacetylate and activate peroxisome proliferator-activated receptor gamma 
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(PPARy) coactivator-ln (PGC-In) to promote gluconeogenesis following fasting (159). 
The combined role of SIRTI and PGC-In moves beyond the liver, to mitochondrial 
function and global energy metabolism as well. SIRTI-activated PGC-In improves 
mitochondrial function in skeletal muscle and brown adipose tissue, leading to increased 
energy expenditure, enhanced exercise performance, and protection from diet-induced 
insulin resistance (123;150). In addition, SIRTI has been shown to form a complex with 
FOX01 and the promyelocytic leukemia protein PML to activate two insulin 
transcription factors, NeuroD and MafA, which may protect the~-cell from oxidative 
damage (150). 
Recently, it was demonstrated that SIRTI is an upstream activator of AMPK in 
hepatocytes (94). SIRTI activation by resveratrol increased the phosphorylation of LKB 1 
and AMPK. Conversely, AMPK phosphorylation by resveratrol was abolished by 
pharmacological and genetic inhibition of SIRTl, suggesting that the ability of 
resveratrol to stimulate AMPK is dependent on sirtuins (94). In addition, NFK~ is a 
substrate for SIRTI (160). Resveratrol-mediated activation of SIRTI is able to directly 
interact with the Re1A/p65 subunit of NFK~ to inhibit its transcription. SIRTI 
deacetylates RelA/p65 on lysine 310 to prevent NFK~-induced transcription of pro-
inflammatory genes (160). Also, p53 acts as a substrate for SIRTI in several cancer cell 
lines (161). Deacetylation ofp53 is believed to explain some of the anti-cancer properties 
ofSIRTl (161). 
SIRT2: Emerging research is beginning to focus on the function of other SIRT 
homologs (SIRT2-7) in mammalian tissue. SIRT2 is a tubulin-deacetylase protein that 
acts as a mitotic checkpoint to prevent chromosomal instability (162). SIRT2 may delay 
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cell cycle progression and control mitotic exit in cell cycle instabilities. Studies has 
shown that SIRT2 plays an important role in the pathology of brain tumor gliomas (162). 
In fact, SIRT2 is often downregulated or deleted in human gliomas, thus increasing their 
malignant progression (163). In addition, it was recently shown that SIRT2 may also play 
a role in myelinogenesis, as it was demonstrated to be localized to the outer loops of the 
myelin sheath in humans (150). 
SIRT3: The SIRT3 protein deacetylase is localized in mitochondria and functions 
to regulate thermogenesis in mice (164). Upon exposure to cold temperatures, the 
expression of SIRT3 is upregulated in both white and brown adipose tissue. In addition, 
SIRT3 also activates mitochondrial genes such as PGC-lu and UPC-l to modulate core 
body temperature (164). 
SIRT4: This sirtuin homolog has been shown to be expressed in mitochondria 
and inhibit mitochondrial glutamate dehydro~enase (GDH) (165). Interestingly, SIRT4 
appears to work in the opposite direction of SIRTI to regulate insulin secretion by 
inhibiting GDH activity to prevent insulin secretion in mouse ~-cells, in response to 
amino acids (165). Furthermore, the expression of SIRT4 is decreased in response to CR 
in ~-cells, which is the reverse of SIRTI expression during CR (165). 
SIRT 5: The expression of SIRT5 is found only in mitochondria; however the 
function of SIRT5 is currently unknown. 
SIRT6: The function of SIRT6 is to regulate genomic DNA stability and DNA 
repair (166). SIRT6 has been demonstrated to deacetylate histones, as well as the DNA 
repair enzyme, DNA polymerase ~ in vitro. Studies using SIRT6-1- mice die prematurely 
and suffer from severe glucose homeostasis imbalance (166). These SIRT6-1- mice 
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experience similar pathologies that are found in elderly humans, implicating that SIRT6 
may playa role in maintaining organ integrity as mice age. 
SIRT7: The SIRT7 protein deaceytlase is the only sirtuin to be completely 
localized in the nucleolus (167). SIRT7 is a component of the RNA polymerase I 
transcription mechanism that interacts with histones and functions to promote the 
transcription of rDNA during transcriptional elongation (167). Studies that caused SIRT7 
deletion prevented cell proliferation and induced cell apoptosis (168). Interestingly, 
SIRT1 works to oppose SIRT7 by negatively regulating RNA polymerase I via 
deacetylation of TAF168 (168). Table 4 reviews the expression and role of each 
mammalian sirtuin homolog in regulating different disease states. 
Various inhibitors of the HDACs have been employed to examine their role in 
cell signalling. These inhibitors are specific to the each class of HDAC and have been 
used extensively for in vitro studies (94;99). Small molecules that inhibit the class IIII 
HDACs are no able to inhibit sirtuins (class III) and vice versa. Trichostatin A is a potent 
and reversible inhibitor of class I/II HDACs that does not effect class III ofHDACs (169). 
Sirtuins (class III HDACs) are inhibited by nicotinamide via it's ability to condense with 
the high-energy enzyme, 2' -O-acetyl-ADP-ribose, to reverse the reaction to reform 
NAD+ as seen in figure 10 (170). In doing so, nicotinamide operates as a classical non-
competitive product inhibitor of the forward deacetylation reaction in sir2 proteins. 
Conversely, splitomicin is believed to mediate sirtuin inhibition by competing for 
acetylated substrate binding (170). Finally, sirtinol is a cell-permeable 2-hydroxy-l-
napthaldehyde derivative that acts as a direct inhibitor of the sirtuin class of histone 
deacetylases (169). 
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Figure 10: The enzymatic pathway of sirtuin activity (152; 171) 
1.61 The Antidiabetic Properties of Resveratrol 
Resveratrol has been shown to acutely increase glucose uptake in L6 (99) and 
C2C 12 (l00) skeletal muscle cell. The proposed mechanism of resveratrol action to 
increase glucose uptake in skeletal muscle cells is via AMPK activation, which is 
independent of the insulin signaling cascade (99; 1 00). In addition, in the presence of 
insulin, cells pretreated with resveratrol were able to improve insulin sensitivity, and 
promote increased insulin-stimulated activity of PI3-K, Akt , and increased glucose 
uptake (l00). 
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Table 4: Expression, localization, and function of the mammalian sirtuin deacetylases 
SIRT Cellular 
Homolog Location Target Genes Link with Diseases Reference 
SIRT1 Nuclear/ p53, NFkB, PGC-1 a, ageing, obesity, insulin Baur et al 2006 (114) 
Cytoplasmic PPARy, Foxo resistance, diabetes Lagouge et al 2006 (119; 
SIRT2 Cytoplasmic a-tubulin down regulated in human Ii Youcef et aI2007(145) 
gliomas Dryden et al 2003 (156) 
SIRT3 Mitochondrial PGC-1 a, AceCS2 breast cancer, adaptive Shi et al 2005 (158) 
thermogenesis 
SIRT4 Mitochondrial Glutamate inhibits amino acid-stimulated Haigis et al 2006 (159) 
dehydrogenase insulin secretion 
SIRT5 Mitochondrial unknown unknown li Youcef et aI2007(145) 
SIRT6 Nuclear DNApol~ age-related diseases Mostoslavsky et al 2006 (160) 
SIRT7 Nuclear RNA polymerase, overexpressed in thyroid Ford et al2007 (162) 
Pol1 cancer and breast cancer Grummt et al2003 (161) 
It has also been proposed that resveratrol enhances glucose uptake (99) in L6 
skeletal muscle cells and insulin sensitivity in C2C 12 skeletal muscle cells via a SIRT 1-
dependent mechanism (172). Studies by Sun et aI, 2007 using palmitate induced-insulin 
resistant C2C12 cells, showed that resveratrol significantly increased insulin-stimulated 
glucose uptake and improved insulin-stimulated Akt phosphorylation. Resveratrol also 
enhanced glycogen synthesis in HepG2 cells in a SIRTI-dependent manner, indicating a 
possible effect of resveratrol to increase insulin action in its target tissues (172). 
In addition to in vitro studies, resveratrol has been shown to increase insulin 
sensitivity and survival in mice fed a high-calorie diet in vivo (118). Compared to mice 
fed 60% of calories from fat (HF-diet), both glucose and insulin levels were significantly 
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diminished in mice that were resveratrol and HF fed. The possible mechanism behind 
these metabolic effects were believed to be mediated by AMPK activation (118). 
Similarly, resveratrol has been shown to possess insulin-like effects In 
streptozotocin-induced diabetic rats (STZ-DM) (173). Su et ai, 2006 observed that 
resveratrol has hypoglycemic and hypolipidemic effects in STZ-DM rats. The STZ-DM 
rats that were treated with resveratrol were orally fed resveratrol by gastric intubation at 
0.1,0.25,0.5, or 0.75 mg/kg body weight, and were sacrificed on day 14. When analyzed, 
the resveratrol treated STZ-DM rats had their plasma glucose concentration reduced by 
25%, and their triglyceride levels reduced by 50% respectively, compared to untreated 
STZ-DM rats (173). This study also concluded that resveratrol administration ameliorates 
common diabetic symptoms, such as polyphagia, polydipsia, and weight loss. 
Furthermore, in STZ-nicotinamide DM rats (a model of moderate insulin-deficient DM), 
resveratrol treatment significantly reduced insulin secretion and delayed the onset of 
insulin resistance (173). 
In addition, studies by Sun et aI, 2007 have shown that resveratrol attenuates high 
fat diet-induce insulin resistance in skeletal muscle in mice in vivo, at a dose of 
2.5mglkg/day, through SIRT1 activation. Mice that were fed a high fat diet exhibited 
impaired glucose tolerance, but in the presence of resveratrol (2.5mg/kg/day) these mice 
had glucose disposal curves comparable to control chow-fed mice. In addition, the SIRT1 
inhibitor nicotinamide was fed to chow diet mice for 8 weeks. Treatment with 
nicotinamide significantly increased fat mass, body weight, and fasting blood glucose 
levels, suggesting that SIRTI activity may regulate insulin sensitivity in vivo (172). 
Furthermore, one study examined the effects of other SIRTI-activators that are 
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structurally different from resveratrol. The oral use of the small molecule activators of 
SIRTI SRT1460, SRT1720, and SRT2183 in both diet-induced obese mice (DIO) and 
genetically obese mice (Zucker) demonstrate improved whole-body glucose homeostasis, 
as well as increased insulin sensitivity compared to their respective control mice (144). 
1.7 RATIONAL 
Skeletal muscle is accountable for more than 75% of whole body glucose uptake 
in response to insulin, and thus quantitatively is the most important insulin target tissue 
(2). Defects in skeletal muscle glucose uptake may lead to decreased insulin sensitivity or 
insulin resistance, leading to the development of type 2 diabetes (49). 
Increased plasma FF As such as palmitate have been linked to insulin resistance in 
vitro and in vivo (34). Studies using L6 and C2C12 skeletal muscle cells have shown that 
palmitate impairs insulin signalling, increases ceramide production, and induces ser307 
and ser636/639 phosphorylation of IRS-l (34;35). Several protein kinases, such as GSK3 
(40), JNK (41;42), PKC's (66), IKK (34), mTOR (45), and p70 S6K (47) have been 
implicated in mediating FFA-induced insulin resistance in vitro and in vivo. These 
kinases can induce insulin resistance by ser307 and ser636/639 phosphorylation of the IRS-l 
protein, which has been shown to cause impairment in the insulin signalling cascade 
downstream of the insulin receptor, and lead to a significant reduction in insulin-
stimulated glucose uptake (36). Palmitate has not been reported to increase the activity of 
the protein kinases JNK, mTOR, and p70 S6K in skeletal muscle cells, which will be the 
focus of our investigation. 
Studies in vivo have also correlated increased palmitate levels with decreased 
insulin-stimulated glucose uptake in skeletal muscle and adipose cells (174; 175). 
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Palmitate impairs the ability of GLUT4 to translocate to the plasma membrane and also 
affects GLUT4 transporter activity, thus preventing glucose entry into insulin sensitive 
tissues (174). In addition, it has been shown that insulin-induced glucose uptake in 
skeletal muscle is considerably decreased in obese subjects that have elevated plasma 
FFA levels (36;176). Thus, investigation of the signalling molecules involved in 
mediating insulin resistance is very important. The knowledge gained from such studies 
could be used towards the development of new treatment strategies. 
The polyphenol resveratrol has been gaining increased popularity in the scientific 
community based on its beneficial biological effects (122; 158). Recent studies have 
proposed resveratrol as an antidiabetic agent (99;123). Resveratrol increases glucose 
uptake in skeletal muscle cells (99) and prevents high fat diet-induced insulin resistance 
in mice ( 118). However, the exact mechanism of resveratrol action needs to be elucidated, 
and therefore further investigation into the antidiabetic effects of resveratrol is required to 
enhance its potential as a therapeutic treatment for insulin resistance and type 2 diabetes. 
1.8 HYPOTHESIS 
In this present study it is hypothesized that; 
1) Resveratrol ameliorates palmitate-induced skeletal muscle insulin resistance. 
2) Resveratrol ameliorates palmitate-induced IRS-l ser307 & ser636/639 phosphorylation, 
3) Resveratrol ameliorates the palmitate-induced decrease in insulin-stimulated Akt 
phosphorylation. 
4) Resveratrol modulates the expression/activation of the protein kinases JNK, mTOR, 
andp70 S6K. 
5) Sirtuins may be involved in the resveratrol mechanism of action. 
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6) AMPK may playa role in the resveratrol-mediated effects. 
1.9 OBJECTIVES 
The primary objectives of this study were; 
1) To examine the effects of resveratrol on palmitate-induced insulin resistance in L6 
skeletal muscle cells. 
2) To examine the effect of resveratrol to modulate the phosphorylation and/or expression 
of IRS-I. 
3) To examine the effect of resveratrol to modulate basal and insulin-induced Akt 
phosphorylation and/or expression. 
4) To investigate the effect of palmitate on the expression and phosphorylation of the 
protein kinases JNK, mTOR, p70 S6K that have been implicated in mediating insulin 
resistance. 
5) To elucidate the role of sirtuins in mediating resveratrol's effects. 
6) To examine possible involvement of AMPK in resveratrol's action. 
The information gathered from this study may be used to further the 
understanding of the mechanisms involved in attenuating skeletal muscle insulin 
resistance. 
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CHAPTER 2: METHODOLOGY 
2.1 Materials 
All tissue culture materials including minimum essential medium (a-MEM), fetal 
bovine serum (FBS), trypsin and antibiotic were purchased from GIBCO Life 
Technologies (Burlington, ON). Antibodies against IRS1, ser307 phospho-IRS 1 , ser636/639 
phospho-IRS1, Akt, phospho-Akt ser473,phospho-Akt ~08, AMPK, phospho-AMPK 
thrl72, JNK, phospho-JNK Thr183/Tyr185, mTOR, phospho-mTOR ser448, p70-S6K, 
phospho-p70S6K Thr389, HRP-conjugated anti-rabbit secondary antibody, and 
ChemiGLOW reagents were purchased from New England Biolabs (Mississauga, ON, 
Canada). ChemiGLOW reagents was obtained through Thermo-Fischer (Ottawa, ON). 
Polyvinylidene difluoride (PVDF) membranes, molecular weight protein standards, and 
electrophoresis reagents were purchased from BioRad (Mississauga, ON). eH]2-deoxy-
D-glucose was purchased from Perkin Elmer (Boston, MA). Chemical inhibitors sirtinol 
and compound C were purchased from Calbiochem (Gibbstown, NJ). All other chemicals, 
including cytochalasin B (CB), protein A agarose beads, NaOH, HCI, NaCl, and albumin 
bovine serum (BSA) were purchased from Sigma (St. Louis, MO). The L6 cells were 
kirtd gift of Dr. A. Klip (Hospital for Sick Children, Toronto, ON). 
2.2 Buffers and Solutions 
A list for the preparation of each buffer and solution used to perform the 
experiments in the methods & results section will be presented below. 
Glucose Uptake Assay: 
HBS Washing Buffer: 140mM NaCI, 5mM KCI, 20mM HEPES, 2.5mM MgS04, ImM 
CaCh , dilute with DD water and fill to 800mL, adjust pH to 7.4 and then fill to lL. 
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Total Radioactive Buffer: HBS buffer, dilute 1: 1000 hot 2-eH]deoxy-D-glucose, and 
1:1000 cold 2-eH]deoxy-D-glucose in HBS. 
Non-specific radioactive buffer: Use total radioactive buffer, add 1: 1 000 cytochalasin B. 
0.9% NaC1: Add 0.9g NaCI per 100ml DD water. 
0.05N NaOH: Add Iml 5N NaOH to 99ml DD water. 
Fatty Acid (FA) Palmitate Solutions: 
Palmitic acid (41mg) was dissolved in bubbling O.IN NaOH (1.6mL) and diluted in 
prewarmed (45-50°C) 9.7% (WN) BSA solution (18.4mL). 
Cell Lysis: 
PBS Washing Buffer: 137mM NaCI, 2.7mM KCI, l.SmM KH2P04, 8.lmM Na2HP04, 
0.68mM CaCI2, 0.49mM MgCI2, add water to lL and adjust pH to 7.4. 
SDS Sample Buffer: 62.SmM Tris-HCI (PH 6.8), 2% w/v SDS, 10% glycerol, 0.01 % 
bromophenol blue, add 0.05% p-mercaptoethanol before use. 
Cell Lysis Buffer: 20mM Tris (PH 7.S), lS0mMNaCI, ImM EDTA, ImM EGTA, 1% 
Triton X-100, 2.5mM sodium pyrophosphate, ImM p-glycerolphosphate, ImM Na3V04, 
1 J.lg/mlleupeptin, add 1 mM PMSF before use and chill on ice. 
Western Blotting: 
l.SM Tris-HCI (pH 8.8): 27.23g Tris base (18.1 Sg/1 OOml), 80ml deionized water, adjust 
to pH 8.8 with 6N HC!. Bring to total volume 150ml with deionized water. 
O.SM Tris-HCI (PH 6.8): 6g Tris base, 60ml deionized water, adjust to pH 6.8 with 6N 
HCI and bring total volume to 100ml with deionized water. 
Resolving Gel Buffer: 12.3ml DD water, 9.9mI30% Acrylamide/ Bis solution, 7.Sml 
1.5M Tris- Hcl, pH 8.8, 0.3mll0% w/v SDS. Right before pouring the gel, add 150, . .tl 
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10% APS (O.Olgi 1OOIll) made fresh daily and l51l1 TEMED and swirl. 
Stacking Gel Buffer: l8.3ml DD water, 3.9mI30% Acrylamide/ Bis solution, 7.5ml 0.5M 
Tris-HCI, pH 6.8, 0.3mI1O% w/v SDS. Right before pouring the gel, add l501l11O% 
APS (O.Olgi 1001ll) made fresh daily and 30111 TEMED and swirl. 
lOx TBS CTris- buffered saline): 24.2g Tris base, 80g NaCI, adjust pH to 7.6 with HCl. 
Use at Ix TBS. Dissolve in lL of water. 
Blocking Buffer: Ix TBS, 0.1 % tween 20, 5% w/v non-fat dry milk. Dissolved in water. 
Primary Antibody Dilution Buffer: 2ml lOx TBS, 18ml water, 1.0g BSA, 20ul Tween- 20. 
Wash Buffer TBS/T: Ix TBS and 0.1% Tween- 20. 
10x Electrode Running Buffer: 15.15g Tris base, 72g Glycine, 5.0g SDS. 
Dissolve and bring volume to 500ml with DD water. Do not adjust pH with acid or base. 
Dilute 50ml of lOx stock with 450ml water before use. 
Transfer Buffer: 25mM Tris base, 0.2M glycine, 20% methanol, dissolved in 800mL of 
water. 
2.3 Parental Rat L6 Skeletal Muscle Cells 
This line of skeletal muscle cells was derived from 72-hour old rat hindlimb 
skeletal muscle (177). These cells start of as mononucleated myoblasts, which were 
cultured in a flask of a-MEM containing 10% FBS. The parental L6 cells then 
spontaneously differentiate into multinucleated myotubes (in a-MEM containing 2% FBS) 
over the course of 5-6 days (177). Once fully differentiated, the myotubes express the 
insulin receptor, insulin receptor substrate-l (IRS-I), and the insulin-sensitive glucose 
transport protein GLUT4 (177). 
Attenuation of skeletal muscle insulin resistance by resveratrol 64 
Using the cell culture methodology is beneficial for studies investigating the 
molecular mechanism of hormones such as insulin, as well as metabolic processes. For 
example, cells in culture are a homogeneous population of cells with little intracellular 
space, unlike primary tissue preparation that may contain a large quantity of unrelated 
supporting tissue. Additionally, the in vitro approach is an isolated environment free from 
external factors that may interfere with cell treatments. Finally, cell culture is efficient 
when investigating acute and chronic effects of various treatments. They can be passaged 
multiple times for repetition and validation of different experimental treatments as well. 
Specifically, L6 myotubes were selected in this study because palmitate-treated 
myotubes is an established model of insulin resistance, which we used to test our 
hypothesis (34;86). Furthermore, skeletal muscle is the predominant target tissue of 
insulin, and L6 skeletal muscle cells are insulin responsive. L6 myotubes also express the 
GLUTI and GLUT4 glucose transport proteins. 
2.4 Cell Culture Technique 
L6 rat skeletal muscle cells were grown in a-MEM containing 5mM glucose, 10% 
(v/v) FBS, and 1 % (v/v) antibiotic-antimycotic solution (100 U/ml penicillin, 100 Ilg/ml 
streptomycin, and 250 ng/ml amphotericin B) until they reached 60-70% confluence. To 
obtain fully differentiated myotubes, myoblasts were trypsinized and seeded into 6 or 12-
well plates in a-MEM medium containing 2% (v/v) FBS with 1% (v/v) antibiotic. This 
media was replaced every 48h and cells were maintained for 5-6 days until they became 
fully confluent myotubes. Myotubes were serum-deprived for 16h in all experiments. At 
the end of treatment, cells were rinsed with HBS followed by a glucose transport assay or 
cell lysis and western blotting. 
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2.5 Cell Treatments 
Resveratrol was prepared by dissolving the resveratrol powder in 100% absolute 
ethanol. Stock solutions of insulin were prepared using 2% FBS-containing media. A 
solution of the inhibitor sirtinol was prepared in sterile DMSO. A vehicle-treated control 
group was used in parallel with the treatment groups. 
Stock palmitate solution was prepared by conjugating palmitate with FA-free 
BSA (Sigma, St. Louis, MO), as previously reported (34). In brief, sufficient palmitate 
was dissolved in O.IN NaOH and diluted in prewarmed (45-50°C) 9.7% (WN) BSA 
solution to give a stock concentration of 8mM palmitate solution. The final molar ratio of 
free palmitate/BSA was 6: 1. The final concentration of palmitate is indicated in each 
figure. A vehicle-treated control group of BSA was used in parallel with each of the 
treatment groups. 
2.6 [3H]2-deoxy-D-glucose Uptake 
After cell treatment the myotubes were washed 3 times in HBS at room 
temperature. Afterwards, cells were incubated with 300ilL of total radioactive buffer 
(lOIlM) in triplicate, and non-specific radioactive buffer (lOIlM) for 10min at room 
temperature. Glucose transport was stopped by washing 3 times with 0.9% NaCl and cell 
were collected in ImL of 0.05N NaOH. Cell associated radioactivity was determined by 
scintillation counting. Protein concentrations were determined using the protein assay 
protocol from Bio-Rad Laboratories. 
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Glucose uptake assay 
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Figure 11: Schematic diagram of the glucose uptake assay protocol 
2.7 Cell Lysis 
3H-2DG 
L6 cells were grown in 6-well plates until they were fully confluent, followed by 
treatments as indicated in the results section. After treatments, cells were washed two 
times with PBS and placed on ice. PBS was removed and 100J.lL of lysis buffer was 
added to each well of the 6-well plates. Cells were lysed and collected into 1.SmL 
eppendorf tubes, and an equal amount of SDS sample buffer was added to each tube. The 
cell samples were then boiled for Smin and stored in the freezer at -20°C. 
2.8 Protein Assay 
Protein assay dye (BioRad) was prepared and filtered for protein concentration 
determination. BSA protein standards (0, 0.1, 0.2, 004, 0.6, 0.8, 0.9, 1.0mg/ml) were used 
to create a standard protein curve. lOlll of each protein standard and lysed samples were 
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pipetted into separate wells of a 96-well plate in triplicate. 200J.!L of protein assay dye 
was then added into each well. The absorbance was measured using a microplate reader 
at 595nm, and the final concentration of the protein samples were calculated in Microsoft 
excel. 
2.9 Immunoprecipitation of IRS1 
200J.!g of whole celllysates were incubated with IRS! antibody (at a 1:50 volume 
ratio) overnight a 4 DC. This was followed by addition of protein A agarose beads (Sigma, 
St. Louis, MO), for 1-3 hours at 4°C. The cell lysate was then microcentrifuged, and 
washed on ice 5 times with cell lysis buffer. The pellet was then resuspended in 20J.!L of 
3x SDS sample buffer and boiled at 100°C for 5min. 15J.!L of protein sample were then 
loaded on a 10% sodium dodecyl sulfate-polyacrylamide (SDS-P AGE) gel and analyzed 
by western blotting. 
2.10 Western blotting 
At the end of the treatment, the cells were rinsed with PBS, followed by the 
addition of lysis buffer. The lysate was scraped off and solubilized in 3x SDS sample 
buffer, followed by separation on a 7-10% SDS-PAGE gel. Samples were then 
transferred from the gel to a PVDF membrane and blocked for Ih at room temperature 
with blocking buffer. After blocking, the membrane was incubated with a primary 
antibody overnight at 4°C. The primary antibody was detected with the appropriate HRP-
conjugated secondary antibody, which was exposed to the membrane for Ih in blocking 
buffer at room temperature. The secondary antibody was visualized by 
chemiluminescense using ChemiGLOW reagent and FluroChem software (Thermo 
Fischer). 
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2.11 Statistical Analysis 
Statistical analysis was performed using SPSS v14.0 software. The results are 
presented as mean ± SEM of at least 3 separate experiments using a student's 
independent sample T-test or the one-way analysis of variance (ANOVA). Statistical 
significance was assumed at P<O.OS. 
CHAPER3: RESULTS 
3.1 ResveratroI restores insulin-stimulated glucose uptake in palmitate treated cells. 
We examined the effect of the free fatty acid palmitate on insulin stimulated 
glucose uptake in L6 myotubes. Acute (30min) stimulation of the myotubes with 100nM 
insulin resulted in a significant increase in 2-eH]deoxy-D-glucose uptake (17S±4.76%, 
compared to untreated control, P<O.Ol, Fig 12). Incubation with O.2mM palmitate for 16 
hours significantly decreased insulin-stimulated 2-eH]deoxy-D-glucose uptake (112 ± 
9.1S% of control, P<O.Ol, Fig 12), indicating insulin resistance. In the presence of 
resveratrol (2Sj.lM), palmitate-treated cells showed significant restoration of insulin-
stimulated 2-eH]deoxy-D-glucose uptake (140 ± 7.14%, P<O.OS, Fig 12). These data 
indicate that the negative effect of palmitate on insulin-stimulated glucose uptake is 
largely ameliorated in the presence of resveratrol. Incubation with palmitate or resveratrol 
alone did not alter basal glucose uptake compared to control cells (92.S ± S.S%, and 92 ± 
4.7% of control respectively, Fig 12). 




Figure 12: Effects of the fatty acid palmitate and the polyphenol resveratrol on glucose 
uptake in L6 myotubes. L6 myotubes were incubated with or without 0.2 mM palmitate 
in the presence or the absence of 251lM resveratrol for 16 h at 37°e, followed by 
stimulation with or without 100nM insulin for 30 minutes. eH]2DG uptake was 
preformed as indicated in the method section. The results are the mean ± SE of 4-8 
independent experiments, each performed in triplicate and expressed as a percent of 
control (*P<0.05, **P<O.Ol). 
3.2 Resveratrol prevents palmitate-induced ser307 & ser636/639 phosphorylation of 
IRS! 
Once insulin resistance was established at the glucose uptake level, we examined 
the effects of palmitate and resveratrol downstream of the insulin receptor. We first 
investigated the effects of palmitate on IRS-l expression and phosphorylation. Previous 
studies using L6skeletal muscle cells in vitro and rats muscle in vivo have shown that 
increased ser307 & ser636/639 phosphorylation of IRS-l impairs insulin signalling and leads 
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to insulin resistance (49;178). Using a phospho-specific antibody we examined 
phosphorylation of the IRS-l protein on ser307 and ser636/639 residues. 
Myotubes that were treated with palmitate (O.4mM) for 16h demonstrated a 
significant increase in ser307 & ser636/639 phosphorylation ofIRS-I (149 ± 18% of control, 
P<O.OS, and IS2 ± 10.3% of control, P<O.OS respectively, Fig 13A, 12B). Treatment of 
the cells with 2S)lM resveratrol for 16h had no significant effect on the basal ser307 & 
ser636/639 phosphorylation levels of IRS-l (101 ± 7.3% of control, and lOS ± 9.1 % of 
control, respectively). However, resveratrol completely abolished the palmitate-induced 
increase in ser307 & ser636/639 phosphorylation of IRS-l (114 ± 7.6% of control, P< O.OS, 
and 103 ± 6.3% of control, P<O.OS respectively, Fig 13A, 12B). The total levels ofIRS-I 
did not change significantly with any treatment (PAL: 101 ± 1O.S% of control, RES: 99 ± 
6.2% of control, RES+PAL: 98 ± 3.6% of control, Fig 12A, 12B). In summary, these 
results clearly indicate that ser307 & ser632/639 phosphorylation of IRS-l is significantly 
increased by palmitate and resveratrol abolishes this effect. 
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Figure 13: Effects of resveratrol and palmitate on IRS-l expression and ser307 & ser636/639 
phosphorylation. A) Myotubes were incubated with or without O.4mM palmitate in the 
presence or absence of 25flM resveratrol for 16h. After treatment the cells were lysed 
and IRS-l was immunoprecipitated as indicated in the methods section. SDS-PAGE was 
performed, followed by immunoblotin~ with specific antibodies that recognize total or 
phosphorylated IRS-l (ser307 and ser63 /639). A representative immunoblot is shown. B) 
The densitometry of the bands expressed in arbitrary units was calculated for total and 
phosphorylated (ser307 & ser636/639) IRS-l using Alpha innotech software. The values are 
the mean ± SE of three separate experiments (* P<O.05). 
3.3 Resveratrol restores insulin-stimulated Akt phosphorylation in palmitate treated 
myotubes 
Next, we examined the effect of palmitate in the absence or presence of 
resveratrol on insulin-stimulated Akt phosphorylation and expression. Myotubes that 
were treated with palmitate for 16h demonstrated a significant decrease in insulin 
stimulated Akt phosphorylation on both ser473 and thr308 residues (PAL+INS: 65 ± 8.1 % 
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of INS, P<0.05, and 57 ± 7.3% of INS, P<0.05, respectively, Fig 14A-B), which is in 
agreement with other studies (35). However, in the presence ofresveratrol, the decline in 
insulin-stimulated Akt phosphorylation on ser473 and thr30S seen with palmitate was 
prevented (RES+PAL+INS: 87 ± 10.5% of INS, P<0.05, and 91 ± 9.8% of INS, P<0.05, 
respectively, Fig 14A-B). Resveratrol had no effect on insulin-stimulated Akt 
phosphorylation (Ser473 INS: 214 ± 5.6% of control, and RES+INS: 218 ± 6.2% of 
control respectively, and on Thr30S INS: 210 ± 7.1% of control, and RES+INS: 207 ± 
8.0% of control, Fig 14C-D) Treatment of the cells with palmitate or resveratrol alone 
had no significant effect on the basal phosphorylation (Ser473 : 101 ± 10.2% of control, 
and 98.3 ± 8.4% of control respectively, and on Thr30S: 102 ± 4.3% of control, and 99.2 ± 
5.1 % of control respectively, Fig 14C-D) The total levels of Akt were not significantly 
changed with any treatment (INS: 104 ± 5.2% of control, PAL: 98 ± 6.3% of control, 
RES: 97 ± 4.9% of control, RES+INS: 105 ± 7.4% of control, PAL+INS: 89±2.6% of 
control and RES+PAL+INS: 94±4.5% of control, fig 14). 
3.4 Palmitate does not affect JNK expression and phosphorylation 
After we established that chronic treatment with palmitate induces ser307 & 
ser636/639 phosphorylation of IRS-I, we attempted to determine the signalling molecules 
that may mediate it. JNK is a serine/threonine kinase that can be activated by many 
environmental stresses, such as radiation, growth factors, cytokines like tumor necrosis 
factor alpha (TNFa) or interleukin-l P (IL-l P), and elevated FF A (54). Phosphorylation 
of JNK at ThrlS3/TyrlS5 has been highly correlated with increased JNK activity (179). 
Activated, JNK has been shown to induce ser307 phosphorylation of IRS-l in liver, 
muscle, and adipose tissue (62). In addition, phosphorylated JNK (ThrI83/TyrlS5) was 
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increased in rats fed a diet high in saturated fat (64). Given that palmitate is a saturated 
fat, the possibility existed that palmitate increased JNK phosphorylation and/or 
expression. 
A) C) 
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Figure 14: Effects ofresveratrol and palmitate on insulin-stimulated Akt phosphorylation 
and expression. A,C) Myotubes were incubated with or without 0.75 mM palmitate in 
combination with or without 10 flM resveratrol for 16h. Myotubes were subsequently 
stimulated with 100 nM of insulin for 10 minutes. The cells were lysed and SDS-P AGE 
was performed, followed by immunobloting with specific antibodies that recognizes total 
or phosphorylated Akt (ser473 and thr308). A representative immunoblot is shown. B,D) 
The densitometry of the bands exr,ressed in arbitrary units was calculated for total and 
phosphorylated Akt (ser473 & thr30 ) using Alpha innotech software. Values are means ± 
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Figure l5A-B showed that palmitate for l6h (109.2 ± 5.27% of control) had no 
effect on JNK phosphorylation and expression. Exposure of the cells to palmitate for 2h, 
6h, or l2h had no effect on phospho-JNK as well (Fig 15C). In addition, palmitate had no 
significant effect on total levels of JNK at l6h (101.1 ± 4.82% of control, Fig 15A-B). 
Acute insulin stimulation (100nM, for 30min) was used as a positive control (Fig 15A-B), 
since it is well documented to stimulate JNK phosphorylation. Indeed acute stimulation 
with insulin resulted in 310 ± 74.5%, P<O.Ol in JNK phosphorylation compared to 
control. Acute insulin treatment had no effect on the total levels of JNK (112.7 ± 3.71% 
of control, Fig 15). 25JlM resveratrol for l6h had no effect on the phosphorylation or 
expression of JNK (96 ± 5.7% of control, and 103 ± 3.9% of control respectively, Fig 
l5D-E). These findings suggest that JNK is not involved in palmitate-induced insulin 
resistance in L6 cells. 
3.5 Resveratrol prevents palmitate-induced phosphorylation of mTOR in L6 
myotubes 
Chronic activation of the serine/threonine kinase mTOR has been shown to impair 
insulin action in L6 myotubes and 3T3-L1 adipocytes (56;180). Furthermore, mTOR is 
known to become activated by hyperinsulinemia (38), and decrease glucose uptake 
through ser307 phosphorylation of IRS-l in muscle, liver, and adipose tissue of mice (56). 
To examine if mTOR involved in palmitate-induced insulin resistance, myotubes were 
incubated with palmitate in the presence or absence of resveratrol for l6h and total and 
phosphorylated levels ofmTOR were examined. 
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Figure 15: Effect of palmitate on JNK expression and phosphorylation. A,C,D) 
Myotubes were treated with 0.4 mM palmitate for 2h, 6h, 12h, and 16h. Another group of 
cell were treated with 25/lM resveratrol for 16h or 100 nM of insulin for 10min. The cells 
were lysed and SDS-PAGE was performed, followed by immunobloting with sEecific 
antibodies that recognize total JNK or phosphorylated JNK (Thr l83/Tyr l 5). A 
representative immunoblot is shown. B,E) The densitometry of the bands expressed as 
arbitrary units was calculated for total and phosphorylated (ThrI83ITyrI85)JNK (fig 14b) 
using Alpha innotech software. Values are means ± SE of four separate experiments 
(* * P<O.O 1). 
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Palmitate treated cells (O.4mM) for 16h showed a significant increase in mTOR 
phosphorylation (149 ± 2.51 % of control, P<0.05, Fig 16A-B). However, myotubes that 
were pretreated with 25~M resveratrol showed complete abolishment in mTOR 
phosphorylation (83.3 ± 7.07% of control, P<0.05, Fig 16A-B). Resveratrol alone had no 
effect on the phosphorylation of mTOR (96 ± 4.8% of control, Fig 16C-D) The total 
levels of mTOR were not significantly changed with any treatment: palmitate 104 ± 
7.13% of control, resveratrol 103 ± 4.3% of control, and palmitate in the presence of 
resveratrol 16h 97.1 ± 6.07% of control (Fig 16). 
3.6 Resveratrol prevents palmitate-induced phosphorylation of p70 S6K in L6 
myotubes 
To examine weather p70 S6K plays a role in palmitate-induced insulin resistance 
we measured its expression and phosphorylation. Myotubes treated with O.4mM 
palmitate for 16h showed a significant increase in p70 S6K phosphorylation (155 ± 
10.5% of control, Fig 17A-B). Cells treated with palmitate in the presence of 25~M 
resveratrol for 16h demonstrated complete abolishment in p70 S6K phosphorylation (92 
± 9.0% of control, Fig 17 A-B). Resveratrol alone had no effect on the phosphorylation of 
p70 S6K (98 ± 4.5% of control, Fig 17C-D). There were no significant changes in the 
total levels of p70 S6K with any treatments: palmitate 16h 95.9 ± 5.9% of control, 
resveratrol 102 ± 6.3% of control or palmitate in the presence of resveratrol 16h 95.4 ± 

























Figure 16: Effects ofresveratrol and palmitate on mTOR phosphorylation and expression. 
A,C) Myotubes were incubated with 0.4 mM palmitate in the presence or absence of 
25J..lM resveratrol for 16 h. The cells were lysed and SDS-PAGE was performed, 
followed by immunobloting with specific antibodies that recognizes total or 
phosphorylated mTOR (ser2448). A representative immunoblot is shown. B,D) The 
densitometry of the bands expressed in arbitrary units was calculated for total and 
phosphorylated (ser2448)mTOR using Alpha innotech software. Values are means ± SE of 
three separate experiments (* P<0.05). 
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Figure 17: Effects of resveratrol and palmitate on p70 S6K phosphorylation and 
expression. A,C) Myotubes were incubated with 0.4 mM palmitate in the presence or 
absence of 251lM resveratrol for 16 h. The cells were lysed and SDS-PAGE was 
performed, followed by immunobloting with specific antibodies that recognizes total 
p70-S6K and phosphorylated (Thr389) p70 S6K. A representative immunoblot is shown. 
B,D) The densitometry of the bands expressed in arbitrary units was calculated for total 
and phosphorylated (Thr389) p70 S6K using Alpha innotech software. Values are means ± 
SE of three separate experiments (* P<0.05). 
3.7 The effect of resveratrol to prevent phosphorylation of IRS-I, mTOR, and S6K 
is sirtuin-dependent 
Resveratrol has been established to activate sirtuins, the NAD+ dependent 
deacetylases. Recent studies have suggested SIRTI to playa role in insulin sensitivity, 
:,' Attenuation of skeletal muscle insulin resistance by resveratrol 79 
energy metabolism, and glucose homeostasis (144). To investigate whether resveratrol 
mediates its effects through sirtuins we used sirtinol, a potent inhibitor of sirtuins. 
Myotubes were treated as before, but in the presence of 50J..lM sirtinol, the ability 
ofresveratrol to prevent palmitate-induced phosphorylation oflRS-l (se~07 and ser636/639) 
and phosphorylation/activation of mTOR, and p70 S6K was blocked (131 ± 5.2% of 
control P<0.05, 167 ± 9.2% of control P<O.OI, and 160 ± 5.4% of control P<0.05, 
respectively, Fig 18). Sirtinol alone had no effect on total or phosphorylated levels of 
IRS-I, mTOR, and p70-S6K (Total: 103 ± 2.5% of control, 102 ± 1.3% of control, and 
103 ± 2.3% of control, phospho: 108 ± 23% of control, 90± 9.7% of control, and 52 ± 
4.6% of control, respectively, Fig 18). 
3.8 The effect of resveratrol to restore insulin-stimulated Akt phosphorylation in 
palmitate treated myotubes is sirtuin-dependent 
In addition, we examined the effect of the sirtuin inhibitor on the expression and 
phosphorylation of Akt on both ser473 and thr308 residues. Sirtinol alone (50J..lM, 16h) had 
no effect on Akt phosphorylation (108 ± 11.9% of control, Fig 19C-D) or expression (107 
± 8.1 % of control, Fig 19C-D). However, in the presence of sirtinol the ability of 
resveratrol to prevent the palmitate-induced decrease in insulin-stimulated Akt 
phosphorylation was abolished (67 ± 10.5% of insulin alone, P<0.05, and 61 ± 7.7% of 
INS, P<0.05, respectively, Fig 19A-B). These data indicated that sirtuins may mediate 















Figure 18: Effects of sirtinol, resveratrol, and palmitate on the phosphorylation and 
expression of IRS-I, mTOR, and p70 S6K. Myotubes were treated with or without 
50!!M sirtinol in the presence or absence of 25!!M resveratrol and/or OAmM palmitate for 
16h. The cells were lysed and SDS-PAGE was performed, followed by immunobloting 
with specific antibodies that recognizes total IRS-I, mTOR, p70-S6K, and 
phosphorylated IRS-l (ser307 and ser636/639), mTOR (ser2248), p70-S6K (TmJ89). A 
representative immunoblot of these separate experiments is shown. 
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Figure 19: Effects of sirtinol, resveratrol, and palmitate on Akt phosphorylation and 
expression. A,C) Myotubes were treated with or without 50llM sirtinol for 16h, in the 
presence or absence of IOIlM resveratrol and/or OAmM palmitate for 16h. The cells were 
then stimulated with 100nM insulin for 10min, followed by cell lysis. SDS-P AGE was 
performed, proceeded by immunobloting with specific antibodies that recognize total or 
phosphorylated (ser473 and thr308) Akt. A representative immunoblot is shown. B,D) The 
densitometry of the bands expressed in arbitrary units was calculated for total and 
phosphorylated (ser473 & thr308) Akt using Alpha innotech software. Values are means ± 
SE of four separate experiments (* P<O.05). 
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3.9 The effect of resveratrol to stimulate AMPK phosphorylation is sirtuin-
dependent 
Previous studies by our group indicate that resveratrol acutely increases glucose 
uptake through increased AMPK phosphorylation that may be mediated by sirtuins (99). 
In the present study, we investigated the chronic (16h) effect of resveratrol on the 
phosphorylation of AMPK, and we examined whether sirtuins are upstream of AMPK 
using nicotinamide a well established inhibitor of sirtuins. 
Chronic resveratrol treatment (25J..lM, 16h) significantly increased the 
phosphorylation of AMPK (RES: 173 ± 14.2% of control, P<0.05, Fig 20A-B), even in 
the presence of O.4mM palmitate (RES+PAL: 169 ± 4.8% of control, P<0.05, Fig 20A-B). 
However, in the presence of the sirtuin inhibitor, nicotinamide (6mM, 16h), resveratrol-
stimulated AMPK-phosphorylation was completely abolished (NIC+RES: 106 ± 7.0% of 
control, and NIC+RES+PAL: 110 ± 9.2% of control, Fig 20A-B) indicating that sirtuins 
may be upstream of AMPK. Palmitate alone had no effect on the phosphorylation of 
AMPK (104 ± 6.4% of control, Fig 20C-D). The expression levels of AMPK did not 
change with any treatment (RES: 107 ± 6.7% of control, NIC: 101 ± 9.2% of control, 
PAL: 98 ± 4.7% of control, NIC+RES: 104 ± 5.6% of control, RES+PAL: 98 ± 5.9% of 
control, and NIC+RES+PAL: 99 ± 8.1 % of control, Fig 20). 
A} 
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Figure 20: Effects of nicotinamide, resveratrol, and palmitate on the phosphorylation and 
expression of AMPK. A,C) Myotubes were incubated with or without 6mM nicotinamide 
for 16h in the presence or absence of25flM resveratrol or OAmM palmitate for 16 h. The 
cells were lysed and SDS-PAGE was performed, followed by immunobloting with 
specific antibodies that recognizes total and phosphorylated (Thrl72) AMPK. A 
representative immunoblot is shown. B,D) The densitometry of the bands expressed in 
arbitrary units was calculated for total and phosphorylated (Thrl72) AMPK using Alpha 
innotech software. Values are means ± SE of three separate experiments (* P<O.05). 
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CHAPTER 4: DISCUSSION 
4.1 Resveratrol Ameliorates Palmitate-Induced Insulin Resistance 
Insulin resistance is highly correlated with obesity and elevated FF As, which are 
risk factors for the development of type 2 diabetes (36). Thus, therapeutic approaches to 
prevent FF A-induced insulin resistance would be beneficial. Previously, the FF A 
palmitate has been shown to induce insulin resistance in skeletal muscle cells (86;87). 
Indeed, our findings demonstrated that there was a significant reduction in insulin-
stimulated glucose uptake in myotubes that were chronically treated for 16h with 0.2mM 
palmitate (fig 12). However, palmitate had no effect on basal glucose uptake. 
Given that skeletal muscle is the main target for glucose disposal in the post-
prandial state, and is the major target of insulin action, it is expected that new 
interventions improving glucose transport in this tissue would be desirable. Recently, it 
was demonstrated that resveratrol attenuates high-fat diet-induced insulin resistance in 
skeletal muscle tissue of mice in vivo (172). Additionally, studies in C2Cl2 skeletal 
muscle cells have shown that treatment with resveratrol have significantly increased 
insulin-stimulated glucose uptake and improved insulin signalling by modulating 
molecules downstream of the insulin receptor (100). These studies are in agreement with 
our findings, in that resveratrol attenuates palmitate-induced insulin resistance, through 
the modulation of key signalling molecules in L6 skeletal muscle cells. 
·We have shown that chronic 16h treatment with 25~M resveratrol did not alter the 
basal levels of glucose uptake, although it has been established that acute treatment with 
resveratrol increases glucose uptake in vitro (99;100). In the presence of 25~M 
resveratrol, palmitate-treated cells showed significant restoration of insulin-stimulated 
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glucose uptake (fig 12), indicating that resveratrol prevents palmitate-induced insulin 
resistance. 
4.2 Elucidating the Mechanism of Action of Resveratrol in Insulin-Resistant 
Myotubes 
Palmitate-induced phosphorylation of IRS-Ion its ser307 & ser636/639 residues is 
known to mediate insulin resistance in skeletal muscle (49;53). Serine phosphorylated 
IRS-I makes a poor substrate for the insulin receptor, thereby inhibiting its downstream 
effects (37). Our results show that myotubes chronically treated for 16h with O.4mM 
palmitate cause a significant increase in IRS-l ser307 and ser636/639 phosphorylation (fig 
13). However, in the presence of 25~M resveratrol palmitate-induced ser307 & ser636/639 
phosphorylation of IRS-l was completely abolished. 
Downstream of IRS-l in the insulin signalling cascade is the serine/threonine 
kinase Akt. This protein is required for insulin-stimulated GLUT4 translocation and 
facilitated entry of glucose into skeletal muscle (1 ;29). Studies using small interfering 
RNA (siRNA) to deplete Akt in 3T3-Ll cultured adipocytes have demonstrated that 
insulin-stimulated glucose uptake is completely abolished, indicating that it is a key 
player in insulin signalling (33). We examined the phosphorylation of Akt at ser473 and 
thr308, which are required for Akt activation (181). Inhibition of insulin-stimulated 
phosphorylation of Akt was observed in L6 myotubes that were chronically incubated 
with O.75mM palmitate for 16h, (fig 14), as seen by other reports (35). However, Akt 
phosphorylation was restored in myotubes that were treated with palmitate in the 
presence of lO~M resveratrol for 16h (fig 14). The concentration of palmitate and 
resveratrol used in this experiment are in close proximity to other studies that 
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demonstrated improved glucose uptake and phosphorylation of Akt in insulin resistant 
C2C12 skeletal muscle cells (172). However, these concentrations of resveratrol are far 
greater (10-1000 times) that the maximal plasma concentrations found in human subjects 
following oral administration of resveratrol, due to its rapid metabolism (182). 
JNK is an insulin-responsive serine/threonine kinase that has been implicated in 
mediating insulin resistance via ser307 phosphorylation of IRS-I (62). Sustained 
activation of JNK was seen in primary mouse hepatocytes and pancreatic l3-cells of high-
fat diet-induced insulin resistant mice and streptozotocin (STZ)-induced diabetic mice. In 
contrast, mice with a targeted mutation at the JNK locus that abolished JNK expression, 
proved to be resistant to high fat-induced insulin resistance (62). We examined the effect 
of OAmM palmitate on phosphorylation of JNK and found that it had no effect (fig 15), 
suggesting that FF A-induced phosphorylation of JNK may be tissue specific. 
The mTOR and p70 S6K pathways have also been suggested to regulate FFA-
induced insulin resistance (79). The activity of mTOR and p70 S6K are increased in the 
liver and skeletal muscle of rats that are fed high-fat diet (47; 183), indicating that this 
signalling pathway may playa role in inducing insulin resistance in vivo (79). In vitro the 
effect of mTOR-induced insulin resistance is largely reversed using the mTOR inhibitor 
rapamycin (56). Similarly, knockout mice that have a S6KI deletion exhibit decreased 
IRS-l phosphorylation on ser307 and ser636(i39 subjected to a high-fat diet when compared 
to their wild-type counterparts (56). 
The phosphorylation of mTOR and p70 S6K was significantly increased when 
myotubes were chronically treated for 16h with OAmM palmitate (fig 16, 17). Similar 
results were observed in obese rats fed a high-fat diet, which lead to increased mTOR 
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activity (180). This observation provides a possible mechanism of action for palmitate to 
induce skeletal muscle insulin resistance, via activation of this pathway. However, 
myotubes chronically treated with palmitate in the presence of 25JlM resveratrol 
demonstrated complete inhibition of palmitate-induced mTOR and p70 S6K 
phosphorylation. This suggests that resveratrol may ameliorate palmitate-induced insulin 
resistance through inhibition of the mTOR and p70 S6K pathway, since both protein 
kinases are known to serine phosphorylate IRS-I. (fig 16, 17). 
4.3 Resveratrol Ameliorates Palmitate-Induced Insulin Resistance through Sirtuins 
Our results demonstrated that the effect of resveratrol to prevent palmitate-
induced ser307 and ser636/639 phosphorylation of IRS-l was inhibited in the presence of 
50JlM sirtinol a sirtuin inhibitor, which suggests that sirtuins may play a role in 
resveratrol's mechanism of action (fig 18). In a recent study by Zhang et aI, 2007 it was 
shown in rat hepatocytes that SIRTI is associated with the IRS proteins, and regulates 
insulin-stimulated tyrosine phosphorylation of IRS-l via deacetylation (154). It is 
possible that the observed resveratrol effects in our study are mediated by a similar 
activation of sirtuins which is associated with IRS-l to prevent its ser307 and ser636/639 
phosphorylation. However, the effects of resveratrol to inhibit mTOR and p70 S6K was 
also abolished by sirtinol (fig 18). Thus, the possibility exists that resveratrol goes 
through sirtuins to inhibit mTOR and p70 S6K phosphorylation, thereby ameliorating 
ser307 and ser636/639 phosphorylation of IRS-I. 
Previously, it has been reported that resveratrol mediates its antidiabetic 
properties, in part through activation of SIRTI (123;144) and AMPK (100;118). Recently, 
it has been shown that AMPK is upstream of SIRTI in skeletal myoblasts that underwent 
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glucose restriction (184). In contrast, SIRTI was recently shown to be an upstream 
regulator of AMPK to control hepatocyte lipid metabolism (94). It is therefore not clear 
whether sirtuins are upstream or downstream of AMPK. In agreement with previous 
studies by our group and other (94), we observed that the resveratrol-stimulated 
phosphorylation of AMPK was completely abolished in the presence of the sirtuin 
inhibitor, nicotinamide (fig 20). This suggests in our cells that sirtuins are upstream of 
AMPK, as has been suggested in hepatocytes (94). 
In addition, we observed that the ability of resveratrol to restore insulin-stimulated 
Akt phosphorylation in the presence of palmitate was attenuated by sirtinol (fig 19). This 
suggests that the effect of resveratrol to improve Akt phosphorylation may also be 
dependent on sirtuins. 
Taken together, we hypothesized that resveratrol exerts its effect through the 
AMPK and sirtuins to attenuate palmitate-induced phosphorylation of mTOR and p70 
S6K (as shown in figure 21). In addition, sirtuin inhibition through the use of sirtinol 
prevents the ability of resveratrol to block palmitate-induced mTOR and p70 S6K 
activation, thereby allowing subsequent serine phosphorylation of IRS-I. 
In conclusion, our results indicate that palmitate induces skeletal muscle insulin 
resistance that was correlated with increased phosphorylation of mTOR and p70 S6K and 
increased ser307 and ser636/639 phosphorylation of IRS-I. We observed that resveratrol 
inhibits palmitate-induced insulin resistance in L6 myotubes. In addition, resveratrol 
significantly decreased ser307 and ser636/639 phosphorylation of IRS-l and restored the 
insulin-stimulated phosphorylation of Akt. 









Figure 21: Proposed mechanism of resveratrol action to prevent palmitate-induced 
insulin resistance in L6 skeletal muscle cells 
On the other hand, the beneficial effect of resveratrol was attenuated in the 
presence of the sirtuin inhibitors sirtinol and nicotinamide. Therefore, a possible 
mechanism of action of resveratrol may involve sirtuins and AMPK. These findings 
implicate resveratrol as a promising therapeutic agent in the attenuation of insulin 
resistance and type 2 diabetes. 
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4.4 Significance of the Present Study 
The prevalence of T2DM is increasing and is expected to affect 380 million 
people globally by the year 2025 (Canadian Diabetes Association). In addition, insulin 
resistance and T2DM is associated with the development of other disease pathologies 
such as cardiovascular disease and cancer (185). Thus new therapeutic approaches to help 
prevent and manage insulin resistance could be beneficial to society. As mentioned 
previously, obesity and the presence of elevated levels of the FF A palmitate, have been 
reported to mediate insulin resistance in skeletal muscle and liver cells (45;118). Recently, 
resveratrol was demonstrated to have antidiabetic properties (144) and to have the ability 
to ameliorate FF A-induced insulin resistance in mice (118). 
This study has shown that palmitate can induce skeletal muscle insulin resistance 
III rat L6 skeletal muscle cells. Palmitate significantly inhibited insulin-stimulated 
glucose uptake and increased the phosphorylation of IRS-Ion numerous serine residues 
(ser307 and ser636/639), thereby preventing downstream insulin signalling. In addition, 
palmitate significantly increased the phosphorylation of mTOR and p70-S6K. 
Importantly, resveratrol prevents the palmitate-induced increase in phosphorylation of 
IRS-I, mTOR, p70-S6K, and restored insulin-stimulated glucose uptake in L6 myotubes. 
These findings are novel and provide compelling evidence for the use of resveratrol in the 
possible treatment of insulin resistance and T2DM. 
4.5 Future Directions 
The role of the AMPK pathway in mediating resveratrol's effects could be 
examined more extensively by using the AMPK inhibitor compound C or siRNA 
approach. If AMPK is indeed playing a significant role in the mechanism of action of 
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resveratrol we would expect that inhibition of AMPK would counteract the positive 
effects of resveratrol on palmitate-induced insulin resistant in L6 myotubes. Similarly, 
future studies could utilize specific sirtuin inhibitors or siRNA approach to investigate the 
role of sirtuins. Based on recent reports (94;154;172) that indicate SIRTI plays a role in 
insulin signalling and insulin sensitivity, it is valid to examine the role of the SIRTI 
sirtuin homolog on resveratrol-mediated attenuation of palmitate-induced insulin 
resistance in L6 myotubes. If SIRTI is inhibited we would expect that the ability of 
resveratrol to ameliorate palmitate-induced insulin resistance would be abolished. 
To provide stronger evidence for the involvement of mTOR and p70-S6K as 
mediators of palmitate-induced insulin resistance in our cells, the mTOR inhibitor 
rapamycin could be utilized. It is expected that rapamycin would have the same effect as 
resveratrol to ameliorate palmitate-induced insulin resistance in L6 myotubes. A similar 
approach would be to use siRNA against mTOR andlor p70 S6K. 
This study used an established model of palmitate-induced skeletal muscle insulin 
resistance in vitro (34;35). The methodology of this study was based on examining the 
phosphorylation and expression of proteins in the insulin signalling cascade (IRS-I, Akt, 
JNK, mTOR, p70 S6K) and AMPK using immuno-blotting. Our study only examined the 
ser307 and ser636/639 phosphorylation sites of IRS-I. Future research could study the effect 
of skeletal muscle insulin resistance on the ser612 and ser1l01 phosphorylation sites ofIRS-
1, as well as tyrosine phosphorylation levels of IRS-I. We would predict that tyrosine 
phosphorylation of IRS-l is decreased in the presence of palmitate and that resveratrol 
can attenuate this effect. Furthermore, the results from immuno-blotting measure the 
phosphorylation levels of proteins on specific residues that are correlated with protein 
" 
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activity. To provide stronger evidence of protein activation, in vitro activity assays could 
be incorporated into future studies. 
GSK3 and PKC have been implicated in the modulation of skeletal muscle insulin 
resistance and could be examined in the future. In addition, the IKKlNFK~ and immune 
response pathway has also been highly correlated to FF A-induced insulin resistance (186). 
Toll-like receptor 4 (TLR4) are a family of receptors that playa role in the innate 
immune system by activating pro-inflammatory signalling pathways, such as IKK and 
NFK~ in response to microbial pathogens (187). Recent studies have shown that the 
activity of TLR4 is increased in lipid-infused mice and obese individuals (187). It has 
also been reported that resveratrol can directly inhibit NFK~ activity (160). Thus, future 
studies could examine the effect palmitate on the immune response pathway in L6 
myotubes. We would expect that resveratrol could attenuate insulin resistance mediated 
through the TLR4 and IKKlNFK~ pathway. 
Future research should also focus on in vivo studies. A rat/mouse model of FF A-
induced insulin resistance could be used to examine the physiological effects of 
resveratrol and its mechanism of action. Additionally, primary tissue cultures of adipose, 
liver, and skeletal muscle tissue could be obtained from these in vivo models to assess the 
effects of resveratrol and FF A in each insulin target tissue. 
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